



HAL
open science

Structure, Activity, and Function of the Protein Lysine Methyltransferase G9a

Coralie Poulard, Lara Noureddine, Ludivine Pruvost, Muriel Le Romancer

► **To cite this version:**

Coralie Poulard, Lara Noureddine, Ludivine Pruvost, Muriel Le Romancer. Structure, Activity, and Function of the Protein Lysine Methyltransferase G9a. *Life*, 2021, 11 (10), pp.1082-10.3390/life11101082 . hal-03870111

HAL Id: hal-03870111

<https://hal.science/hal-03870111>

Submitted on 27 Feb 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Review

Structure, Activity, and Function of the Protein Lysine Methyltransferase G9a

Coralie Poulard ^{1,2,3,*}, Lara M. Nouredine ^{1,2,3,4}, Ludivine Pruvost ^{1,2,3} and Muriel Le Romancer ^{1,2,3} 

¹ Cancer Research Cancer of Lyon, Université de Lyon, F-69000 Lyon, France;

nouredinelara@gmail.com (L.M.N.); ludivine.pruvost@etu.univ-lyon1.fr (L.P.);

Muriel.LEROMANCER-CHERIFI@lyon.unicancer.fr (M.L.R.)

² Inserm U1052, Centre de Recherche en Cancérologie de Lyon, F-69000 Lyon, France

³ CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, F-69000 Lyon, France

⁴ Laboratory of Cancer Biology and Molecular Immunology, Faculty of Sciences, Lebanese University, Hadat-Beirut 90565, Lebanon

* Correspondence: coralie.poulard@lyon.unicancer.fr

Abstract: G9a is a lysine methyltransferase catalyzing the majority of histone H3 mono- and dimethylation at Lys-9 (H3K9), responsible for transcriptional repression events in euchromatin. G9a has been shown to methylate various lysine residues of non-histone proteins and acts as a coactivator for several transcription factors. This review will provide an overview of the structural features of G9a and its paralog called G9a-like protein (GLP), explore the biochemical features of G9a, and describe its post-translational modifications and the specific inhibitors available to target its catalytic activity. Aside from its role on histone substrates, the review will highlight some non-histone targets of G9a, in order gain insight into their role in specific cellular mechanisms. Indeed, G9a was largely described to be involved in embryonic development, hypoxia, and DNA repair. Finally, the involvement of G9a in cancer biology will be presented.

Keywords: G9a; GLP; H3K9 methylation; protein lysine methylation; EHMT2; EHMT1; protein post-translational modification; cancer



Citation: Poulard, C.; Nouredine, L.M.; Pruvost, L.; Le Romancer, M. Structure, Activity, and Function of the Protein Lysine Methyltransferase G9a. *Life* **2021**, *11*, 1082. <https://doi.org/10.3390/life11101082>

Academic Editors: Albert Jeltsch and Arunkumar Dhayalan

Received: 2 September 2021

Accepted: 8 October 2021

Published: 14 October 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Protein lysine methylation is a dynamic post-translational modification (PTM) regulating protein stability and function. Lysine methylation of histone proteins can modulate transcriptional activity without affecting the DNA sequence itself, enabling dynamic gene transcription patterns in response to environmental stimuli [1]. Lysine methylation is deposited by writer enzymes called protein lysine methyltransferases (PKMTs), removed by eraser enzymes called lysine demethylases (PKDMs) and interpreted by reader proteins that bind to lysine methylation marks. PKMTs catalyze the transfer of the methyl group from the S-adenosyl-L-methionine (AdoMet) donor to the ϵ -nitrogen of a lysine residue on protein substrates [1]. The lysine ϵ -amino group of proteins can accept up to three methyl groups, resulting in either mono-, di-, or trimethyl lysines. To date, more than 50 PKMTs have been reported, with sequence and product specificity. Two PKMT families have been identified: the SET lysine methyltransferases containing the majority of PKMTs [2] and the Seven β -strand methyltransferase (7 β S) or class I family [3]. Histones are methylated on several lysine residues. A growing number of reports also describe the methylation of non-histone proteins on lysine residues [1].

G9a was identified and sequenced in the 1990s [4]. It belongs to the SET PKMT family. G9a was extensively studied as a key enzyme in the mono- and dimethylation of lysine 9 of histone H3 (H3K9me1 and H3K9me2, respectively) in euchromatin [5]. Since the H3K9me2 mark is associated with transcriptional repression, G9a was primarily considered to be an epigenetic repressor [5–7]. Its role as a coactivator of several transcription factors

emerged more recently [8–12]. Though G9a is the most commonly used term for this lysine methyltransferase, it is also known as lysine methyltransferase-1C (KMT1C), euchromatic histone N-methyltransferase 2 (EHMT2), or BAT8 (HLA-B associated transcript 8).

The current review will provide an overview of the structural features of the protein with a particular focus on its paralog GLP (G9a-like protein). The biochemical features of G9a will also be detailed with a special emphasis on the key PTMs affecting G9a and regulating its activity and function. Finally, among the large number of G9a substrates described, including histone and non-histone substrates, the present report will focus on their involvement in specific physiological pathways and their connection to cancer.

2. Structural Features

2.1. Structure and Domain Architecture

In human cells, G9a exists as two isoforms: a full-length isoform of 1210 amino acids (called isoform A) derived from 24 exons of the G9a gene and a splice variant of 1176 amino acids (isoform B) that arises from the excision of exon 10 (Figure 1a). The alternative splicing of G9a is conserved in different species, tissues, and cell lines [13]. Even if the two isoforms are ubiquitously found in different tissues, the ratio between them varies. For example, isoform A is preponderant in the kidney, thymus, and testis, and, interestingly, is more abundant in epithelial cell lines compared to mesenchymal cell lines and more transformed cell lines [13]. Mauger et al. reported that the two isoforms display similar methyltransferase activities and subcellular localizations. Likewise, Fiszbein et al. showed that isoform B expression increased during neuronal differentiation [14]. They did not report any change in G9a catalytic activity following exon 10 inclusion, but demonstrated that exon 10 inclusion increases G9a nuclear localization in a neuronal cell line [14]. Mouse G9a is also subjected to alternative splicing. Full-length mouse G9a protein contains 1263 amino acids and shares more than 90% homology with human G9a [15].

G9a belongs to the Su(var)3-9 family of methyltransferases, which was first identified in *Drosophila melanogaster* [16]. The main characteristic of this family of proteins is the presence of a highly conserved SET domain [17]. SET, an acronym for Su(var)3-9, Enhancer-of-zeste and Trithorax, is a long sequence of 130 to 140 amino acids, characterized in 1998, that has a unique structural fold [17]. The SET domain is composed of a series of β strands that fold into three sheets and surround a knot-like structure [18]. The conserved core of the SET domain is flanked by a pre-SET (nSET) domain providing structural stability by interacting with different surfaces of the core SET domain, and a post-SET (cSET) domain responsible of the formation of a hydrophobic channel via an aromatic residue [19]. Neither pre-SET nor post-SET domains are conserved across KTM SET domains, as they vary in size and tertiary structure [20]. In the core SET domain, G9a contains an inserted i-SET domain (Figure 1a). The i-SET domain forms a rigid docking platform and a substrate binding groove with the post-SET domain in three-dimensional structures [21]. The G9a SET domain contains four structural zinc fingers for proper folding and enzymatic activity. A cluster of three Zn^{2+} ions is chelated by nine cysteines, whereas the fourth Zn^{2+} ion, adjacent to the S-adenosylmethionine (SAM)-binding site, is chelated by four cysteines [22]. The binding of AdoMet and the protein substrate occurs on opposite sides of the SET domain. AdoMet binds and positions its methyl group at the base of the channel, while the side chain of the target lysine protrudes into the channel [20]. Within the SET domain, the tyrosine residue Y1154 was demonstrated to be essential for the catalytic activity of G9a [23]. The tyrosine may allow deprotonation of the positively charged ammonium group in order to favor methylation.

G9a also contains a cysteine-rich region, a polyglutamate region and seven ankyrin repeats of 33 amino acids (Figure 1a). The ankyrin repeat domain was reported to be a mono- and dimethyllysine binding module, a reader domain important for protein-protein interactions [24]. The specificity of the G9a ankyrin repeat domain is comparable to the specificity of other groups of reader proteins recognizing methyl binding protein modules, such as the chromodomain, the tudor domain, or the PHD finger domain [24]. G9a was

the first protein described to harbor within a single polypeptide, the signal to catalyze and read the same epigenetic marks, H3K9me1, and H3K9me2 [24].

A nuclear localization signal was identified in the N-terminal region of human G9a [25], and amino acids 1-280 of human G9a were shown to act as a coactivator domain in transient reporter gene assays [10] (Figure 1a).




Figure 1. Schematic representation of the structure and domains of human G9a (a) and GLP (b). G9a and GLP contain different domains: an activation domain (AD), a Cys-rich region (Cys), an ankyrin repeat domain (ANK), and a SET domain composed of a core SET domain associated with pre- and a post-SET domains. G9a and GLP contain a nuclear localization signal (NLS). G9a also contains a Glu-rich region (E) and GLP a Glu/Asp-rich region (E/D). (c) Sequence alignment of G9a (NP_006700.3) and GLP (NP_079033.4). The alignment was performed using the MultAlin program [26] (<http://multalin.toulouse.inra.fr/multalin>) (accessed on 7 October 2021). Amino acids with 100% and >60% conservation are shown in red and blue, respectively.

2.2. GLP, a G9a Paralog

A paralog of G9a was identified and called G9a-like protein (GLP), though it is also termed lysine methyltransferase-1D (KMT1D) or euchromatic histone N-methyltransferase 1 (EHMT1) (Figure 1b). G9a and GLP share 45% sequence identity and around 70% sequence similarity (Figure 1c) [2]. They differ primarily in the N-terminus, and present a high level of conservation in the SET domain with over 80% shared sequence identity (Figure 1c) [27]. The main difference in structure between the two proteins concerns the E-rich domain of G9a, which is composed of a sequence of repeated glutamic and aspartic acid residues in the case of GLP (Figure 1b,c). In addition, binding affinities of the ankyrin domains of G9a and GLP for H3K9 differ, as GLP and G9a preferentially bind to mono- and dimethylated H3K9, respectively [24,28].

G9a and GLP form homo- and heterodimers via their SET domains in complex with ZNF644 and WIZ [6,29–31]. In the endogenous complex, they act mainly as heterodimers in a large variety of human cells [6]. However, *in vitro*, independently of each other, G9a and GLP are able to catalyze lysine methylation by forming homodimers. Extensive research has focused on G9a, albeit GLP seems to be equally important for most biological phenomena ascribed to G9a. Indeed, GLP generally possesses similar catalytic activities as G9a [29]. However, the individual effects of G9a and GLP are hard to study, as G9a depletion destabilizes GLP [6,32].

3. Biochemical Features

3.1. Sequence Specificity

The majority of studies conducted on G9a sequence specificity focused on Histone H3. *In vitro*, the minimum substrate recognition site of seven amino acids of H3 is composed of residues 6 to 11 (TARKSTG), with a consensus methylation site encompassing RK/ARK [33]. The arginine residue adjacent to the lysine residue is essential for G9a activity [33]. G9a preferentially acts when a hydrophobic amino acid is positioned before the arginine residue, such as alanine. After the lysine residue, G9a favors a hydrophilic residue followed by a hydrophobic one. This G9a recognition site is present in several non-histone proteins, as well as on its N-terminal domain [34–36].

Several biochemical studies have shown that specific PTMs affect the catalytic activity of G9a. For instance, phosphorylation of S10 or T11 of H3 impairs G9a catalytic efficacy [33,36]. In addition, R8 of H3 can be methylated by the arginine methyltransferase PRMT5 *in vivo*, and this event impairs methylation of H3K9 by G9a [36]. Indeed, a decrease in methylation of over 80% was reported for peptides carrying an asymmetric dimethylation of R8, a methylation mark catalyzed by PRMT5 [36].

3.2. Product Specificity

G9a mainly catalyzes mono- and dimethylation events, as illustrated with H3K9 [6,24]. However, several reports demonstrated that G9a also generates, after a long incubation time, trimethylation of H3K9 (H3K9me3) [25,37]. Investigations on G9a-deficient cells demonstrated that G9a is the major H3K9me1 and H3K9me2 methyltransferase of euchromatin [5].

Biochemically, the specificity of G9a methylation for a particular state is largely due to a tyrosine residue in its active site. Indeed, Y1067 controls whether G9a catalyzes mono-, di- or trimethylation of lysines; Y1067 mutation to F1067 allowing G9a trimethylation of H3K9 [21]. Mechanistically, Y1067 forms hydrogen bonds with the nitrogen atom of the ϵ -amino group of the target lysine residue [21].

3.3. Regulation

3.3.1. PTMs

As for most proteins, G9a is subjected by many PTMs that regulate its ability to bind new partners and impact its cellular functions (Figure 2). Further details about their cellular features will be given in the corresponding sections below.




Figure 2. G9a undergoes several post-translational modifications including methylation (M), phosphorylation (P), sumoylation (S), and hydroxylation (H). The numbers indicate amino acid (aa) residues.

G9a was shown to be auto-methylated on lysine 185 (K185) and phosphorylated by the Aurora kinase B (AurKB) on the adjacent threonine 186 (T186) in the N-terminal domain of the protein [35] (Figure 2). Heterochromatin protein 1 proteins (HP1 α , HP1 β , HP1 γ) and CDYL (chromodomain Y-like) were identified as specific partners that bind methylated G9a [34,35]. These proteins contain chromodomains functioning as methyl-lysine binding modules. Of note, a similar methylation and phosphorylation switch on adjacent residues was previously demonstrated for the histone H3 [38,39]. H3K9me2 methylated by G9a recruits HP1 proteins, whereas H3 phosphorylated on S10 by AurKB has an opposite effect [38,39]. Like G9a, GLP is also auto-methylated on lysine 205 (K205) and phosphorylated by AurKB on threonine 206 (T206) [32]. Both G9a and GLP auto-methylation sites can be demethylated by the KDM4 lysine demethylase family [40]. Sampath et al. found no evidence of a role for G9a auto-methylation in the regulation of G9a enzymatic activity [35].

Additionally, G9a was shown to be phosphorylated on two serine residues involved in DNA damage repair, namely Serine 211 (S211) phosphorylated by casein kinase 2 (CK2) and serine 569 (S569) phosphorylated by ATM kinase (Figure 2) [41,42]. Interestingly, phosphorylation of G9a on S211 does not change its methyltransferase activity and G9a catalytic inhibitor does not affect G9a phosphorylation on S569 [41,42].

G9a is sumoylated in skeletal myoblasts in order to regulate its transcriptional activity [43]. This event acts as a signal for the recruitment of the histone acetyltransferase PCAF (p300/CBP-associated factor) to E2F1 target genes, implicated in cell cycle progression by increasing the level of histone H3 lysine 9 acetylation [43].

Casciello et al. demonstrated that G9a stability is regulated by proline hydroxylation catalyzed by oxygen sensors, as inhibition of the latter increased protein stability [44]. Authors showed that G9a hydroxylation is detected in normoxic conditions, whereas it is not detected under hypoxia. Proline hydroxylation occurs on proline residues 676 (P676) and 1207 (P1207) in consensus hydroxylation motifs LXXLAP and leads to efficient degradation by the proteasome (Figure 2) [44]. G9a is also hydroxylated in the ankyrin repeat domain of G9a on asparagine 779 (N779) by the asparaginyl hydroxylase factor inhibiting HIF (FIH) (Figure 2) [45]. This event impedes G9a binding to methylated H3K9 products and to di- and trimethylated H3K9. Hydroxylation of N779 destabilizes the interaction of H3K9me2 with the ankyrin repeat domain of G9a by disrupting the structural pocket that facilitates methyl binding [24,45]. Likewise, GLP is hydroxylated on N867 [45].

3.3.2. Stability

G9a protein stability relies on the presence of GLP, as GLP depletion also decreases G9a expression [6,32]. Using G9a^{-/-} and GLP^{-/-} embryonic stem cells, Tachibana et al. reported that G9a is more stable in the G9a/GLP heteromeric complex. This observation did not apply to GLP [6]. The protein WIZ was reported to be a key partner of both G9a and GLP to stabilize the G9a/GLP heteromeric complex [30]. Both WIZ and GLP depletion decreases G9a protein levels, suggesting that the WIZ/G9a/GLP complex protects G9a from degradation [30]. Later, Bian et al. mapped the specific sequence of WIZ interacting with G9a/GLP. They showed that WIZ only interacts directly with the NTD of GLP [31]. Its interaction with G9a might be indirect and mediated by the fact that G9a and GLP form heterodimers. WIZ contains multiple zinc finger motifs, targeting the G9a/GLP complex to chromatin in order to mediate H3K9 methylation [31].

3.4. Substrates

3.4.1. Histone Substrates

In 2001, Tachibana et al. identified the first substrates of G9a as histone proteins [46] (Table 1). They demonstrated that G9a was able to add methyl groups to H3 on lysine 9 and lysine 27 [46]. Since then, G9a has largely been described as the major PKMT catalyzing the mono- and dimethylation of H3K9 [5], and, to a lesser extent, H3K9 trimethylation [25,37]. Though H3K9 methylation is well known for its role in transcriptional silencing [6,47], the impact of H3K27 methylation by G9a emerged more recently. Wu et al. demonstrated in

2011 that even though H3K27me2/3 is not affected in G9a^{-/-} ES cells, H3K27me1 levels were clearly lower in these cells [48]. G9a also methylates H3 on lysine 56 (H3K56me1) in order to maintain proper DNA replication [49], a methylation event that was shown to be induced by DNA damage [41].

Table 1. List of histone substrates of G9a and their biological outcome. Nd: not determined.

Histone Types	Sites	Biological Outcome	References
Histone H3	H3K9me1 H3K9me2 H3K9me3	Transcriptional repression Heterochromatin formation	[5,25,37]
Histone H3	H3K27me1	Transcriptional repression Heterochromatin formation	[46,48]
Histone H3	H3K56me1	DNA replication	[49]
Histone H1.2	H1.2K187me	nd	[51]
Histone H1.4	H1.4K26me1 H1.4K26me2	Transcriptional repression Chromatin structure	[50]

G9a methylates histone H1 in a variant-specific manner. Human cells have 11 H1 variants, two of which were shown to be methylated by G9a, namely isotype 2 (H1.2) and isotype 4 (H1.4) [50,51]. H1.4 was reported to be mono- and dimethylated on H1.4K26. This event provides a recognition site for HP1 binding, establishing a proper chromatin surface and suggesting a role for H1.4K26me1/2 in transcriptional repression [50]. G9a methylates H1.2 on K187 in vitro and in vivo. However, H1.2K187me2 is not recognized by HP1 proteins, demonstrating selective recognition by these proteins [51]. Weiss et al. demonstrated that G9a does not directly bind to methylated histone variants, suggesting a different mechanism from that observed in H3K9me1/2 to achieve methylation [51].

3.4.2. Non-Histone Substrates

G9a also methylates a large number of non-histone proteins involved in several biological functions listed in Table 2. Most of these are linked with transcriptional regulation, as G9a methylates numerous transcription factors, chromatin remodeling factors, and coregulators.

3.5. Inhibitors

Among the numerous G9a inhibitors, there are three different types: (i) substrate competitive inhibitors, (ii) SAM cofactor competitive inhibitors and (iii) inhibitors by ejection of Zn²⁺ ions. Substrate competitive inhibitors act by binding to G9a substrate binding sites, while SAM inhibitors prevent G9a-mediated methylation by interacting with SAM binding sites on G9a [52]. Most of these inhibitors also impact GLP [53].

3.5.1. Substrate Competitive Inhibitors

Substrate competitive inhibitors specifically bind to the substrate binding site of G9a. The first substrate competitive inhibitor discovered was BIX01294, a quinazolin derivative able to inhibit H3K9me2 [70]. Many studies then sought to optimize this inhibitor by enhancing its G9a specificity, efficacy and by reducing cell toxicity. Based on Structure-Activity Relationship studies (SAR), modifications of BIX01294 provided more specific and powerful G9a inhibitors including UNC0224, UNC0321, UNC0638, UNC0646 [52]. The majority of G9a substrate competitive inhibitors impede G9a activity by interacting with two G9a aspartate residues in the SET domain (D1074 and D1083) [71,72]. Recently, by adding and expanding the 1,4 benzodiazepine cycle, Milite et al. improved UNC0638 potency and named it EML741 [73].

Table 2. List of substrates of G9a categorized by their biological functions. Nd: not determined.

Functions	Substrates	Site	Biological Outcome	References
Transcription Factors	C/EBP β	K39	Inhibits transcriptional activity by repressing C/EBP β transactivation	[54]
	MyoD	K104me1/2	Inhibits MyoD transcriptional activity	[55]
	MEF2D	K267me1/2	Inhibits MEF2D transcriptional activity by preventing its recruitment on chromatin	[56]
	p53	K373me2	Inhibits transcriptional activity and p53-dependent apoptosis	[57]
	ER α	K235me2	Induces transcriptional activity by recruiting the PHF20/MOF HAT complex	[58]
	Foxo1	K273me1/2	Induces Foxo1 degradation	[59]
	KLF12	K313	nd	[36]
Chromatin remodeling factors and coregulators	G9a	K185me2/3	Induces specific glucocorticoid receptor transcriptional activity by recruiting HP1 γ	[32,34,35]
	GLP	K205me2	Induces specific glucocorticoid receptor transcriptional activity by recruiting HP1 γ	[32]
	Sirt1	K662	nd	[60]
	Pontin	K265, K267, K268, K274, K281, K285	Induces HIF-1 transcriptional activity by enhancing p300 recruitment	[61]
	Reptin	K67me1	Inhibits HIF transcriptional activity by recruiting corepressors	[62]
	HDAC1	K432	nd	[36]
	HIF α	K674me1/2	Inhibits HIF-1 transcriptional activity	[63]
	CSB	K170, K297, K448, K1054	nd	[36]
	MTA1	K532me1	Inhibits transcription by recruiting the assembly of the NuRD repressive complex	[64]
	ATF7IP (hAM)	K16me3	Induces transgene silencing by recruiting MPP8	[65]

Table 2. Cont.

Functions	Substrates	Site	Biological Outcome	References
Chromatin binding protein	CDYL1	K135me3	Decreases its interaction with H3K9me3	[36]
	WIZ	K305me3	nd	[36]
	DNMT1	K70me2	nd	[36]
DNA methyltransferases	DNMT3	K47me2	Inhibits transcription by recruiting MPP8/DNMT3/G9a/GLP repressive complex	[66]
	Acinus	K654me2	nd	[36]
	MDC1	K45me2	Induces ATM accumulation on damage sites	[67]
Others	Plk1	K209me1	Antagonizes T210 phosphorylation to inhibit Plk1 activity on DNA replication	[68]
	Lig1	K126me2/3	Maintenance in DNA methylation by promoting UHRF1 recruitment to replication foci	[69]

3.5.2. SAM Competitive Inhibitors

The cofactor SAM is the methyl donor essential for G9a-mediated methylation. SAM competitive inhibitors compete with SAM to bind to the SAM binding site of G9a. The first inhibitor of this class to be identified by Kubicek et al. was BIX01338, discovered around the same time as BIX01294 [70]. Analogous inhibitors were then synthesized with similar structures, such as BRD9536 and BRD4770 [74]. However, this type of inhibitor remains less specific than substrate competitive inhibitors, as it also downregulates the enzymatic activity of several other PKMTs [52].

3.5.3. Inhibition by Ejection of Structural Zn²⁺

Lastly, Lenstra et al. reported that structural zinc ions are essential to maintain the enzymatic activity of the methyltransferases G9a/GLP [22]. By using selenium- or sulfur-containing proteins able to eject the fourth structural zinc ions, they demonstrated that G9a methyltransferase activity could be inhibited. Molecules used clinically such as ebselen, disulfiram, and cisplatin work specifically as inhibitors of G9a and GLP. These findings may offer new perspectives to develop further G9a-specific inhibitors [22].

4. Cellular Features

4.1. Connection with Chromatin Regulation

4.1.1. G9a Corepressor Functions

As mentioned above, G9a is a coregulator with an essential role in repression of gene transcription. Functionally, G9a is involved in several mechanisms, primarily the methylation of the histone H3 N-terminal tail in order to close chromatin (Table 1).

- G9a in Euchromatin

Numerous studies have shown that G9a is recruited to specific target genes as a corepressor by transcription factors, such as CCAAT displacement protein/cut (CDP/cut) [75], growth factor independent 1 (Gfi1) [76], positive regulatory domain I-binding factor 1 (PRDI-BF1) [77], neuron restrictive silencing factor (NRSF) (also known as REST) [78],

multi-domain protein UHRF1 [79], and the noncoding RNA Air [80], in order to remodel chromatin structure. G9a also represses active gene transcription by recruiting other corepressors. For example, in euchromatin, G9a interacts with Polycomb Repressive Complex 2-proteins, including the PKMT EZH2, in order to transcriptionally silence specific regions within the genome (Figure 3a) [81].




Figure 3. G9a acts as a transcriptional coregulator, either as a corepressor (a) or coactivator (b). (a) After G9a recruitment by some transcription factors (TFs), G9a methylates histones (red circles) leading to chromatin remodeling and gene repression. G9a also recruits corepressor proteins (i.e., other PKMTs and chromatin remodelers) and DNA methyltransferases (i.e., DNMT3a and DNMT1) in order to fully repress transcription via histone modifications (i.e., acetylation (orange circles) and DNA methylation (green circles)). Of note, G9a also methylates some TFs and DNA methyltransferases modulating their functions. (b) Conversely, G9a recruitment by the glucocorticoid receptor (GR), estrogen receptor (ER α), RunX2 and NF-E2/p45 leads to gene activation through the recruitment of specific coactivators (CoAct) (i.e., histone acetyltransferases and methyltransferases) and the transcription machinery (i.e., Mediator complex or RNA polymerase II).

- G9a in heterochromatin

In heterochromatin, G9a drives silencing mechanisms by serving as a platform for the formation of repressive complexes. Methylation of H3K9 leads to the recruitment of proteins such as HP1, which can bind to methylated H3K9 via their chromodomains [38,39]. This recruitment is crucial for heterochromatin formation and gene silencing [82]. In addition, G9a also recognizes H3K9 methylation via its ankyrin repeat in order to work as a scaffold for the recruitment of other corepressors [24]. It was shown for instance that G9a interacts with the PKMT Suv39h and SETDB1 in specific regions of heterochromatin to maintain chromosomal stability (Figure 3a) [83].

- G9a and DNA methylation

Other mechanisms underlying G9a repressive function have been identified. For example, the ankyrin repeat domain of G9a was reported to contribute to DNA methylation-mediated repression of transcription by recruiting DNA methyltransferases (DNMT3a and DNMT3b), and by recognizing the H3K9me2 histone mark [24,84]. A specific residue of the ankyrin repeat domain (Asp905) has also been associated with this co-repressive function by maintaining H3K9me2 levels and establishing DNA methylation [85]. In addition, Chang

et al. demonstrated that G9a dimethylates DNMT3a on K47, allowing its recognition by the MPP8 chromodomain [66]. This event results in a silencing complex containing DNMT3a/MPP8/G9a on chromatin that could in part explain the co-occurrence of DNA methylation and H3K9 methylation in chromatin (Figure 3a). Additionally, Smallwood et al reported that HP1 proteins, the readers of H3K9 methylation, target DNMT1 enzyme to euchromatic sites, providing a basis for the generation of CpG methylation [86]. Finally, DNMT1 is methylated by G9a reinforcing the whole model [36] (Figure 3a).

4.1.2. G9a Coactivator Functions

In addition to the well-studied and established co-repressive function of G9a, reports have emerged on its function as a coactivator, by contributing to the activation of gene expression [9–12,32,87,88].

It was suggested that different binding partners may play critical roles in the switch between the coactivator and corepressor functions of G9a. Indeed, G9a stabilizes the occupancy of the Mediator complex on the promoter of the adult β globin gene in a NF-E2/p45-dependent manner to exert its coactivator function, while it recruits the H3K4 demethylase Jarid1a to the promoter of the embryonic β globin gene and results in transcription repression [12,89] (Figure 3b). It has also been shown that G9a is recruited to the promoter or enhancer regions of its positively regulated target genes, indicating that G9a may act directly on their expression [8–12,32,87–89]. In addition, G9a was reported to bind to RNA polymerase II, indicating that G9a may be involved in the establishment of a preinitiation or initiation complex during transcription [12].

The G9a activation domain (AD) (amino acid 1–280 in human G9a) was first identified by Dr. Stallcup's group using transient reporter gene assay [10] (Figure 1). G9a AD is sufficient and required for its coactivator function [10] and contains an autonomous activation domain [9]. Recently, we demonstrated the importance of G9a auto-methylation in the G9a AD for its coactivator function. Indeed, auto-methylation of G9a (K185) is required for its coactivator function with the glucocorticoid receptor (GR), by facilitating the binding of HP1 γ and the subsequent recruitment of RNA pol II [32]. Inversely, G9a phosphorylation (T186) by AurKB antagonizes these effects (Figure 3b). Thus, these adjacent modifications regulate coactivator functions and contribute to determining whether G9a act as a coactivator or corepressor [32]. At the physiological level, we demonstrated that the coactivator activity of G9a regulates migration of the lung cancer cell line, A549 [32], and GC-induced cell death in leukemia [32,88]. In addition, G9a was reported to function as a scaffold protein to recruit the coactivators p300 and CARM1 on a subset of GR target genes, leading to transcriptional activation [8,9].

G9a also acts as a coactivator by specifically methylating the estrogen receptor alpha (ER α) on K235 [58]. This event is recognized by the Tudor domain of PHF20, which recruits the MOF histone acetyltransferase complex in order to acetylate H4K16 and promote active transcription (Figure 3b). Through this mechanism, G9a regulates a specific subset of ER α target genes [58].

4.2. Cellular Roles and Functions

4.2.1. Embryonic Development

Most PKMTs are essential for the formation of healthy embryo, as they remodel histones and control chromatin packaging and transcriptional accessibility along the genome [1]. Hence, it came as no surprise that G9a knockout impacted embryonic development [5]. Embryo of mice genetically engineered to be G9a-deficient displayed delayed development, growth arrest by the earliest stages monitored, and were no longer viable by embryonic day 9.5 [5]. Histones extracted from G9a-deficient embryos showed a strong decrease in H3K9me2 [5,6] Later studies, then reported the importance of G9a in specific developing tissues and organs based on different analyses.

- Germ Cell Development

Germ line-specific G9a knockout mice were shown to be sterile due to a drastic loss of mature gametes [90]. In addition, completion of meiosis was not observed in either gender. In G9a-deficient germ cells, H3K9me1/2 decreased during meiosis, suggesting that gene silencing induced by G9a is crucial for proper meiotic prophase progression [90].

- Cardiac Development

Engineered mice in which GLP was knocked out and G9a knocked down in cardiomyocytes showed neonatal lethality and atrioventricular septal defects, strongly implicating G9a and GLP in cardiomyocyte function for atrioventricular septum formation [91]. However, cardiomyocyte-specific G9a knockout mice were normal and the loss of G9a induced only a slight decrease in H3K9me2 levels in cardiomyocytes, indicating that adequate H3K9me2 can be performed by enzymes other than G9a in cardiomyocytes [91].

- Neuronal Development

Neuron-specific deficiency of G9a did not reveal obvious neuronal developmental or architectural defects [92]. However, these mice displayed various abnormal phenotypes, including defects in cognition and adaptive behaviors, such as difficulties in learning, motivation and environmental adaptation [92]. Authors demonstrated that multiple non-adult neuronal and non-neuronal progenitor genes were derepressed in the forebrain of these mice deficient for G9a [92]. Using pharmacological inhibition of G9a/GLP activity, it was demonstrated that G9a/GLP are required in the dorsal hippocampus for the transcriptional switch from short-term to long-term spatial memory formation [93]. Repression of G9a and H3K9 methylation has been described in postmortem nucleus accumbens of human cocaine addicts, indicating a clinical relevance of G9a in human addiction [94]. Through extended analyses, Maze et al. demonstrated a role for G9a in neuronal subtype identity in the adult central nervous system, and a critical function for G9a and H3K9 methylation in the regulation of behavioral responses to environmental stimuli [95].

- Bone Formation

G9a protein levels and H3K9me2 were reported to increase during developmental progression in tooth and growth plate cartilage [96]. G9a methyltransferase activity regulates cell proliferation and differentiation in dental mesenchyme in order to promote proper tooth development [96].

Using two different models of conditional G9a knockout mice, G9a was shown to be involved in cranial bone formation, since mutant mice had severe defects in cranial vault bones with opened fontanelles [97,98]. Mechanistically, the effect of G9a on cranial bone formation relies on its function as repressor of Twist expression during osteoblastic differentiation and as coactivator of RunX2 [97,98]. Stallcup's group demonstrated that G9a is able to enhance RunX2-mediated transcription in transient reporter gene assays by acting as a coactivator of RunX2 [11]. RunX2 is a key transcription factor of bone-forming cells by regulating osteoblastic differentiation [99]. Later, Ideno et al. showed that G9a enhances RunX2 transcriptional activity in mesodermal cells through binding and activation of RunX2 [97].

- Other Mechanisms

G9a knockdown or inhibition through pharmacological inhibitors in adult erythroid cells induces re-emergence of a fetal gene program, illustrated by the switch in expression from adult to fetal β -globin isoforms [12,89] (Figure 3).

Conditional knockout of G9a in the skeletal muscle lineage highlighted that G9a has little effect on skeletal myogenesis [100].

Targeted depletion of G9a in the developing mouse retina generated disorganized tissues [101]. According to the authors this was due to the fact that retinal progenitor cells depleted for G9a were highly proliferative and were not able to mature into the specialized components of the retina [101]. Similar results were obtained in zebrafish embryos knocked down for G9a using morpholino antisense oligos [102].

These different studies clearly demonstrated that G9a has a major impact on embryonic development, with roles in various pathologies, including neurological disorders, cardiac pathogenesis, immune cell development, and cancer progression.

4.2.2. Hypoxia

In mammalian cell lines, G9a activity was reported to increase under hypoxic conditions, concomitant to an increase in total H3K9me2 levels, resulting in gene silencing [103]. In G9a^{-/-} mouse embryonic stem cells under hypoxic conditions, the level of H3K9me2 was significantly lower, demonstrating that G9a was involved in hypoxia-induced H3K9me2 [103]. The hypoxic upregulation of G9a was attributed to specific PTMs (Figure 4). As described previously, G9a is hydroxylated at residues P676 and P1207 by PHD1 in order to target G9a toward proteasome degradation via ubiquitinylation [44]. Hypoxia induces PHD1 inhibition and a subsequent upregulation of G9a, leading to an increase in H3K9me2 and the silencing of a specific subset of target genes. Casciello et al demonstrated that G9a inhibition decreases proliferation, migration, and in vivo tumor growth [44]. Likewise, in ovarian cancer, FIH reaction was limited under hypoxia, leading to a reduced expression of metastasis-suppressor genes via H3K9 methylation [45]. Mechanistically, FIH induces hydroxylation of G9a on N779, impairing its ability to bind mono- and dimethylated H3K9, and thus methylate H3K9 [45] (Figure 4).




Figure 4. The role of G9a in hypoxia. (a) In normoxia, PHD-1 hydroxylates G9a on P676 and P1207 leading to proteasomal degradation. Likewise, FIH hydroxylates G9a on N779 impairing its ability to bind to H3K9me1/2 products. These hydroxylation processes are inhibited under hypoxic conditions resulting in an increase in the global level of G9a protein and H3K9me2. (b) In addition, under hypoxia, G9a methylates histones and non-histone targets. Hypoxia increases G9a-dependent H3K9me2 at the promoter regions of several genes leading to their repression. In addition, G9a methylates HIF-1α coregulators Pontin and Reptin during hypoxic stress, leading to the activation and repression of HIF-1α target genes. Finally, HIF-1α methylation by G9a suppresses HIF-1α transcriptional activity under hypoxia.

However, the role of G9a under hypoxia is likely more extensive, as G9a methylates many protein substrates involved in hypoxia, namely Pontin, Reptin, and HIF-1 α [61–63] (Figure 4). Bao et al. demonstrated that HIF-1 α , a master regulator of the hypoxic response, is mono- and dimethylated by G9a on K674 [63]. They demonstrated that G9a is able to methylate HIF-1 α in an oxygen-independent manner. However, endogenous HIF-1 α is unstable and degraded under normoxic conditions, indicating that HIF-1 α is unlikely to be methylated in normoxia [63]. HIF-1 α K674me1/2 suppresses HIF-1 α transcriptional activity under hypoxia and expression of its downstream target genes (Figure 4). These authors also demonstrated that HIF α methylation by G9a decreases HIF-1-dependent migration of glioblastoma cells [63]. In addition, G9a methylates Reptin and Pontin, two chromatin remodelers involved in hypoxia, known to bind to HIF-1 proteins [61,62]. Under hypoxia, G9a monomethylates Reptin on K67 (K67me1), this methylation negatively regulates a subset of hypoxia target genes via the recruitment of Reptin K67me1 to their promoters and an enhanced binding to HIF-1 α [62]. In addition, Reptin K67me1 leads to the recruitment of corepressors such as HDAC1 to hypoxia-responsive gene promoters in order to decrease HIF-1 α transcriptional activity [62] (Figure 4). Conversely, under hypoxia, G9a methylates Pontin on six lysine residues (K265, K267, K268, K274, K281, K285), enhancing p300 coactivator recruitment on the promoters of HIF-1 α target genes, resulting in an increase in HIF-1 transcriptional activity [62] (Figure 4). Although Reptin and Pontin share similarities in their structures, they act as coactivator or corepressor of HIF-1 depending on their subset of target genes in order to modulate cellular responses to hypoxia [61,62].

The ability of G9a to repress genes under hypoxic conditions suggests a key role for G9a in cell survival processes in this condition, especially in solid tumors where hypoxia is a common microenvironmental state.

4.2.3. DNA Damage and DNA Repair

Two reports demonstrated that G9a was recruited to DNA-damage sites, mainly through G9a phosphorylation [41,42]. G9a is phosphorylated by casein kinase 2 (CK2) at S211 in response to DNA double-strand breaks (DSBs), promoting G9a recruitment to sites of DNA damage by increasing its interaction with chromatin, where it can directly interact with replication protein A (RPA) [42]. In turn, binding of G9a to RPA modulates RPA and Rad51 foci formation, allowing efficient homologous recombination of DSBs and cell survival [42]. In parallel, Ginjala et al. demonstrated that G9a is phosphorylated by ATM kinase on S569 [41]. This event also leads to its recruitment to sites of DNA breaks. Authors demonstrated that the catalytic activity of G9a is critical for early recruitment of 53BP1 and BRCA1 to DNA lesions, but dispensable for their late recruitment. Induction of DSBs leads to an increase in H3K9me2 and H3K56me1 in their neighboring chromatin, two histone targets of G9a [41]. Inhibition of the catalytic activity of G9a decreases these modifications, suggesting that G9a could be recruited to DNA breaks in order to induce local histone methylation and subsequent local transcriptional silencing. Finally, using GFP-based reporters of homologous repair (HR) or non-homologous end-joining repair (NHEJ), they demonstrated that the catalytic activity of G9a impairs both mechanisms, HR and NHEJ [41]. Moreover, phosphorylation of S211 and S569 appears to be essential for proper DNA repair [41,42].

G9a may also methylate specific non-histone proteins involved in DNA repair mechanisms, such as Polo-loke kinase 1 (Plk1) and p53 [57,68]. Plk1 phosphorylation on T210 is required during DNA damage repair and checkpoint recovery [104]. Recently Li et al. demonstrated that the activity of Plk1 is controlled by a switch between methylation and phosphorylation, as for G9a and GLP [68]. Authors showed that under DNA damage stress conditions, the interaction between G9a and Plk1 is enhanced and G9a monomethylation on K209 of Plk1 is increased [68]. Interestingly, Plk1 methylation by G9a is not necessary for its recruitment to DNA lesions or for the assembly of the DNA repair machinery via RPA and Rad51 recruitment. However, this methylation is crucial for the timely removal of this DNA repair machinery from DNA lesions, which is essential for the proper completion

of DNA damage repair [68]. The tumor suppressor p53 was also demonstrated to be a substrate for G9a on K373 [57]. However, p53 methylation seems to be link with inactive p53, as the level of methylated p53 during DNA damage does not change even though the total level of p53 increases dramatically [57]. This data is consistent with the fact that catalytic inhibition of G9a using inhibitors under low DNA damage conditions impairs DNA DSB repair in a p53-independent manner [105]. However, it is interesting to note that G9a dimethylation of p53 at K373 increases Plk1 expression and promotes colorectal cancer [106].

These reports clearly demonstrate the relevance of G9a in the maintenance of genome integrity, implicating G9a in cancer biology.

5. G9a in Cancer

5.1. G9a Oncogenic Role

Recently, dysregulations in the PTMs of both DNA and histones were shown to contribute to cancer initiation and progression [107]. These epigenetic modifications, which result in altered chromatin structure and gene expression were reported in different types of cancers [108] (Figure 3). G9a was overexpressed in breast, gastric, ovarian, cervical, endometrial, prostate, lung, colorectal, liver, urinary bladder, and brain cancers, as well as in hematological malignancies, melanoma, and cholangiocarcinoma, leading to aberrant H3K9 methylation [109–122]. One of the main reasons for this increase in G9a expression and H3K9 methylation is hypoxia [103]. The molecular mechanisms associated with this phenomenon are described in a previous section (Figure 4). Furthermore, high levels of G9a expression were associated with poor prognosis and shorter survival in cancer patients [57,123–127]. G9a involvement in cancer biology is likely due to its pivotal role in tumor cell proliferation, survival, and metastasis primarily by controlling several transcription programs (Table 3).

5.1.1. Breast Cancer

High G9a-mediated H3K9 methylation triggers the proliferation and progression of breast cancer (Table 3) [109,128,129]. For instance, G9a overexpression was shown to down-regulate the expression of some tumor suppressor genes, such as ARNTL, CEACAM7, GATA2, HHEX, KLRG1, and OGN. Blocking G9a methyltransferase activity was sufficient to re-express these genes, and consequently inhibit breast cancer cell proliferation and migration in vitro and tumor growth in vivo [44]. G9a was also demonstrated to interact with MYC and suppress its target genes by favoring H3K9me2, in order to stimulate MYC-dependent breast tumor growth [129]. G9a may also contribute to enhancing breast tumor metastasis by silencing several genes implicated in epithelial-mesenchymal transition (EMT), namely the two anti-metastatic tumor suppressor genes, desmocollin 3 (DSC3), belonging to the cadherin superfamily, and the protease inhibitor MASPIN, which were transcriptionally reactivated in a dose-dependent manner upon inhibition of G9a activity, concomitantly to a significant decrease in global H3K9 dimethylation [130]. In addition, in EMT, G9a was shown to repress the expression of E-cadherin, a cell adhesion factor, upon association with the SNAIL transcription factor and to induce H3K9me2 of its promoter [131]. Depletion of G9a restored E-cadherin expression and inhibited breast cancer cell migration and invasion in vitro and in vivo [131]. G9a also silenced the expression of the type-II cadherin CDH10 through histone methylation, stimulating hypoxia-mediated cellular motility; and its inhibition prevented cellular movement and breast cancer cell colonization in the lungs [123]. G9a methyltransferase activity was further reported to (i) collaborate with the transcription factor YY1 and HDAC1 to disrupt cellular iron homeostasis by repressing ferroxidase hephaestin, resulting in iron accumulation and breast cancer progression [109], (ii) induce breast cancer cell autophagy by modulating the AMPK-mTOR pathways [132], and (iii) promote breast cancer recurrence through the suppression of pro-inflammatory genes [133].

5.1.2. Gastric Cancer

In gastric cancer, G9a activation reduces apoptosis and promotes tumor cell growth (Table 3) [134]. For instance, blocking the catalytic activity of G9a reduces cell growth and autophagy by downregulating the mechanistic target of rapamycin (mTOR) pathways. Authors showed that G9a activates mTOR through H3K9 monomethylation at the mTOR promoter [125]. G9a inhibition by (i) kaempferol, a flavonoid present in fruits and vegetables [135], (ii) SH003, an herbal formulation [136], or (iii) cinnamaldehyde (CA), the bioactive ingredient in *Cinnamomum* [137], stimulated autophagic gastric cancer cell death. Increase in H3K9 methylation under hypoxia also mediated the silencing of the tumor suppressor gene, runt-domain transcription factor 3 (RUNX3) [138]. Finally, G9a overexpression was shown to upregulate the expression of ITGB3, an integrin family member, in an enzyme-independent manner inducing gastric cancer metastasis [139].

5.1.3. Human Reproductive Cancers

Alterations in G9a expression were also associated with human reproductive cancers (Table 3). In ovarian cancer (OCa), high G9a expression levels were correlated with late stage, high grade, and a decreased overall survival in OCa patients [111,140]. An elevation in the level of G9a was observed in vitro in invasive cell lines ES-2, SKOV-3, TOV-21G, OV-90, and OVCAR-3, and in vivo in metastatic lesions in comparison with less aggressive tumor cells and primary tumors [111]. Depletion of G9a inhibited cellular adhesion, migration, invasion, and anoikis-resistance of OCa cell lines in vitro and suppressed OCa metastasis in vivo [111]. Further investigations revealed that several tumor suppressor genes were repressed in OCa by G9a, such as DUSP5, SPRY4, CDH1, and PPP1R15A. PARP inhibitor-resistant high-grade serous ovarian carcinoma (HGSOC) displayed an increase in H3K9me2 associated with an increase in the overall expression of G9a [140]. Similar observations were made in vivo on patient-derived xenografts, indicating that a high G9a expression maintains resistance to PARP inhibitors [140]. Interestingly, inhibition of G9a displayed synergistic anti-tumor effects in combination with DNA methylation inhibitors in OCa cell lines, where authors induced cell death by upregulating endogenous retroviruses (ERVs), consequently activating the viral immune response [141].

In cervical cancer, G9a induces the expression of angiogenic factors including angiogenin, interleukin-8, and C-X-C motif chemokine ligand-16, prompting angiogenesis and cancer cell invasion, and decreasing patient survival [142]. Interestingly, depletion of G9a decreased the expression of oncogenic proteins such as Bcl-2, Mcl-1, and Survivin, and increased the expression of E-cadherin inhibiting cell adhesion and invasion [112].

Likewise, in endometrial cancer, G9a-mediated H3K9 methylation induced tumor invasion in vitro and in vivo via the silencing of the E-cadherin [113]. Indeed, G9a depletion reduces H3K9me2 levels, restores E-cadherin expression and decreases E-cadherin promoter DNA methyltransferase recruitment. G9a expression is higher in endometrial cancer tissues and its expression is correlated with deep myometrial invasion [113].

Finally, in prostate cancer, high G9a expression was associated with high pathological grade and poor overall survival. In this model, G9a promoted cancer proliferation by inhibiting PI3K/AKT/mTOR pathway [114].

5.1.4. Lung Cancer

In lung cancer, G9a possesses proliferative and metastatic properties (Table 3) [114]. Highly invasive lung cancer cell lines were reported to display higher G9a protein levels, in comparison with weakly invasive cells. Overexpressing G9a increased cell motility and invasiveness [143]. Different reports demonstrated that G9a induced tumor growth, invasion, and migration by (i) silencing specific EMT-regulating genes, including caspase-1 and the epithelial cell adhesion molecule Ep-CAM [124,144], (ii) mediating the Snail2-induced E-cadherin suppression [145], and/or (iii) activating the focal adhesion kinase signaling pathway [146]. Depletion of G9a abolished lung cancer cell migration and invasion in vitro and metastasis in vivo [124,144,146]. G9a also induced cell proliferation through the activa-

tion of the WNT signaling pathway by suppressing WNT signaling inhibitors like DKK1, APC2, and WIF1 [121]. Moreover, G9a was shown to play an important role in maintaining lung cancer cell stemness by maintaining DNA methylation of multiple lung cancer stem cell genes and their subsequent expression [147].

5.1.5. Colorectal Cancer

In colorectal cancer (CRC), high levels of G9a are associated with tumor initiation, maintenance, and proliferation (Table 3) [59,106,148]. In primary CRC patient samples, transcriptome profiling revealed the co-enrichment of G9a and H3K9me2 of multiple genes involved in the negative regulation of the WNT signaling pathway, in repression of EMT and extracellular matrix organization, leading to their repression in CRC [148]. G9a also methylates two non-histone substrates involved in CRC cell proliferation, FOXO1 (Forkhead family transcription factor) and p53 [59,106]. FOXO1 is methylated by G9a on K273, increasing the interaction between FOXO1 and the E3 ligase SKP2. This event decreases FOXO1 protein stability and promotes cellular proliferation in colon cancer [59]. These authors also demonstrated that G9a protein expression is increased in human colon cancer patient tissue samples associated with a decrease in FOXO1 protein level [59]. Likewise, G9a-mediated p53 dimethylation at lysine 373 was shown to increase Plk1 expression and consequently CRC cell growth [106].

5.1.6. Hepatocellular Carcinoma

In hepatocellular carcinoma (HCC), targeting G9a is suggested as a novel therapy for HCC treatment as it drives tumorigenesis and aggressiveness (Table 3) [149,150]. Indeed, G9a is upregulated in HCC, which leads to the epigenetic silencing of the retinoic acid receptor responder protein 3 (RARRES3) tumor suppressor gene, thus triggering HCC proliferation and metastasis in vitro and in vivo [116]. Moreover, G9a was shown to enhance metastasis formation through an epigenetic regulation of EMT, as it interacts with SNAIL2 and HDACs at the E-cadherin promoter in order to inhibit E-cadherin transcription [151]. A recent study showed that G9a contributes to HCC initiation by escaping p53-induced apoptosis in DNA-damaged hepatocytes via the repression of Bcl-G expression, a pro-apoptotic Bcl-2 family member [152].

5.1.7. Urinary Bladder Cancer

G9a was reported to be upregulated or amplified in urinary bladder cancer (UBC) [153]. G9a represents a promising therapeutic target for UBC as various G9a inhibitors decrease cell proliferation and increase cell death through the endoplasmic reticulum stress pathway [153]. Likewise, targeting G9a and DNMT methyltransferase activity with a novel dual inhibitor called CM-272 induces cell apoptosis and immunogenic cell death [153].

5.1.8. Hematological Cancers

G9a is upregulated in hematological malignancies, for which G9a inhibitors have been identified as promising targets for patient management (Table 3) [154–158]. In T-lymphoblastic leukemia cells (T-ALL), inhibiting G9a activity suppresses cellular proliferation and induces apoptosis by downregulating the expression of Bcl-2 and upregulating the expression of Bax and caspase-3 [155]. Likewise, in chronic lymphocytic leukemia, targeting G9a and GLP was shown to stimulate cancer cell death [154]. In multiple myeloma, G9a fosters RelB-dependent cancer growth and survival, whereas its depletion reduces the expression of RelB and increases the expression of pro-apoptotic genes, such as Bim and BMF [118]. In acute myeloid leukemia (AML), G9a inhibition attenuates the transcriptional activity of the leukemogenic transcription factor HoxA9 and thus promotes AML proliferation, progression, and self-renewal [157]. In childhood acute lymphoblastic leukemia, G9a is reported to enhance the ability of cancer cells to migrate [159].

Table 3. Role of G9a in Cancer Biology.

G9a Roles	Cancer Types	G9a Biological Roles	References
Oncogenic	Breast Cancer	Suppresses tumor suppressor genes Enhances EMT Disrupts iron homeostasis Inhibits autophagy	[44,130] [123,131] [109] [132]
	Gastric Cancer	Suppresses tumor suppressor genes Inhibits apoptosis and autophagy Promotes metastasis	[138] [125,135–137] [139]
	Ovarian Cancer	Promotes metastasis Suppresses tumor suppressor genes Maintains PARP-inhibitor resistance	[111] [45,111] [140]
	Cervical Cancer	Induces angiogenesis Enhances tissue invasion	[142] [112]
	Endometrial Cancer	Enhances tissue invasion	[113]
	Prostate Cancer	Stimulates proliferation	[114]
	Lung Cancer	Enhances EMT Activates WNT signaling pathway Maintains lung cancer stemness Supports resistance to radiotherapy	[124,144,145,160] [121] [147] [161]
	Colorectal Cancer	Stimulates proliferation Enhances self-renewal and stemness Promotes resistance to chemotherapy	[59,106] [148] [162]
	Liver Cancer	Suppresses tumor suppressor genes Enhances EMT Inhibits cell apoptosis	[116] [151] [152]
	Bladder Cancer	Inhibits cell apoptosis and autophagy	[122,153]
	Brain Cancer	Stimulates proliferation Inhibits autophagy	[117,163] [164]
	Hematological malignancies	Enhances self-renewal and stemness Promotes migration Inhibits apoptosis and stimulates proliferation	[157] [159] [118,155]
	Skin Cancer	Promotes progression	[119,165]
	Head and Neck Cancer	Enhances EMT	[166]
	Bile duct Cancer	Suppresses tumor suppressor genes	[120]
Anti-oncogenic	Lung Cancer	Inhibits cancer progression	[167]
Brain Cancer	Inhibits HIF-induced migration Inhibits cancer stemness	[63]	

5.1.9. Other Cancers

G9a represents an intriguing target in various other types of cancers (Table 3). In medulloblastoma, G9a drives H3K9me1/2/3 at the promoter of ubiquitin-specific protease 37 (USP37) to repress its gene expression [163]. USP37 controls cell proliferation by regulating the stability of the cyclin-dependent kinase inhibitor 1B (CDKN1B/p27Kip1) in cell cycle. Thus, blocking G9a inhibits cellular proliferation and tumorigenic potential of medulloblastoma cells [163]. Pre- or post-treatment of glioma cells with a G9a inhibitor sensitizes these cells to Temozolomide (TMZ), the first line therapy for glioblastoma patients, and increases its cytotoxicity [168]. Interestingly, authors demonstrated that the G9a inhibitor reprograms glioma cells and glioma stem-like cells to increase sensitivity to TMZ [164,168]. As previously described in breast cancer, HCC, and lung cancer, G9a interacts with SNAIL in order to mediate repression of E-cadherin and EMT in head and neck squamous cell carcinoma (HNSCC) [166]. Additionally, G9a was associated with cholangiocarcinoma, a highly malignant epithelial tumor of the biliary tree, where G9a-mediated H3K9 methylation suppressed the expression of the tumor suppressor gene LATS2, leading to the subsequent activation of the oncogenic YAP signaling pathway [120]. Recently in melanoma, elevated G9a levels promoted cancer progression through the activation of the WNT/ β -catenin signaling by epigenetic silencing of the WNT antagonist DKK1 gene [165], or through the upregulation of the Notch1 signaling pathway, that further stimulates PI3K/AKT pathway [119].

5.2. G9a Tumor Suppressive Role

In stark contrast to its oncogenic roles, several studies demonstrated that G9a also promotes tumor suppressive functions. For example, G9a depletion increased the aggressiveness of lung tumor propagating cells (TPC) and accelerated disease progression and metastasis [167]. Inhibition of G9a derepresses genes that regulate the extracellular matrix. Patients with high levels of G9a displayed a better survival in early-stage lung cancer [167]. Interestingly, in glioblastoma, G9a inhibited HIF-1 α -mediated migration via the methylation of the alpha subunit at lysine 674 [63].

6. Outlook

Over the last three decades since G9a was discovered, extensive studies were conducted to gain further insight into its physiological and pathophysiological roles. Aside from its key role in epigenetic repression through H3K9 methylation, G9a displays many biological functions, notably in gene expression, associated with its methylation of histone and non-histone substrates. Furthermore, a growing body of evidence indicates that G9a acts as a coregulator of transcription factors and steroid receptors, and could hence endorse other functions through these properties. Owing to its broad implication in biological activities, dysregulation of G9a expression is common to many types of cancers, and, as such, G9a represents a promising target for anti-cancer agents. Indeed, many inhibitors of G9a inhibitors have been synthesized and characterized, and could represent interesting therapeutic agents.

Author Contributions: C.P., L.M.N. and L.P. wrote the manuscript. M.L.R. revised it. All authors have read and agreed to the published version of the manuscript.

Funding: M.L.R., L.M.N., L.P. and C.P.'s laboratory is funded with grants from "La Ligue contre le Cancer", the "Fondation ARC Cancer" and the association "Cancer du sein, parlons en". L.M.N. was supported by a fellowship from AZM & Saadeh Association and Lebanese University.

Acknowledgments: We thank B. Manship for proofreading the manuscript. The illustrations were created by using Servier Medical Art.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Wu, Z.; Connolly, J.; Biggar, K.K. Beyond Histones—The Expanding Roles of Protein Lysine Methylation. *FEBS J.* **2017**, *284*, 2732–2744. [[CrossRef](#)] [[PubMed](#)]
2. Dillon, S.C.; Zhang, X.; Trievel, R.C.; Cheng, X. The SET-Domain Protein Superfamily: Protein Lysine Methyltransferases. *Genome Biol.* **2005**, *6*, 1–10. [[CrossRef](#)] [[PubMed](#)]
3. Falnes, P.; Jakobsson, M.E.; Davydova, E.; Ho, A.; Malecki, J. Protein Lysine Methylation by Seven- β -Strand Methyltransferases. *Biochem. J.* **2016**, *473*, 1995–2009. [[CrossRef](#)] [[PubMed](#)]
4. Milner, C.M.; Campbell, R.D. The G9a Gene in the Human Major Histocompatibility Complex Encodes a Novel Protein Containing Ankyrin-like Repeats the Class III Region of the Human Major Histocompatibility Complex Spans Approx. *Biochem. J.* **1993**, *290*, 811–818. [[CrossRef](#)]
5. Tachibana, M.; Sugimoto, K.; Nozaki, M.; Ueda, J.; Ohta, T.; Ohki, M.; Fukuda, M.; Takeda, N.; Niida, H.; Kato, H.; et al. G9a Histone Methyltransferase Plays a Dominant Role in Euchromatic Histone H3 Lysine 9 Methylation and Is Essential for Early Embryogenesis. *Genes Dev.* **2002**, *16*, 1779–1791. [[CrossRef](#)]
6. Tachibana, M.; Ueda, J.; Fukuda, M.; Takeda, N.; Ohta, T.; Iwanari, H.; Sakihama, T.; Kodama, T.; Hamakubo, T.; Shinkai, Y. Histone Methyltransferases G9a and GLP Form Heteromeric Complexes and Are Both Crucial for Methylation of Euchromatin at H3-K9. *Genes Dev.* **2005**, *19*, 815–826. [[CrossRef](#)]
7. Tachibana, M.; Matsumura, Y.; Fukuda, M.; Kimura, H.; Shinkai, Y. G9a/GLP Complexes Independently Mediate H3K9 and DNA Methylation to Silence Transcription. *EMBO J.* **2008**, *27*, 2681–2690. [[CrossRef](#)]
8. Bittencourt, D.; Wu, D.Y.; Jeong, K.W.; Gerke, D.S.; Herviou, L.; Ianculescu, I.; Chodankar, R.; Siegmund, K.D.; Stallcup, M.R. G9a Functions as a Molecular Scaffold for Assembly of Transcriptional Coactivators on a Subset of Glucocorticoid Receptor Target Genes. *Proc. Natl. Acad. Sci. USA* **2012**, *109*, 19673–19678. [[CrossRef](#)]
9. Lee, D.Y.; Northrop, J.P.; Kuo, M.H.; Stallcup, M.R. Histone H3 Lysine 9 Methyltransferase G9a Is a Transcriptional Coactivator for Nuclear Receptors. *J. Biol. Chem.* **2006**, *281*, 8476–8485. [[CrossRef](#)]
10. Purcell, D.J.; Jeong, K.W.; Bittencourt, D.; Gerke, D.S.; Stallcup, M.R. A Distinct Mechanism for Coactivator versus Corepressor Function by Histone Methyltransferase G9a in Transcriptional Regulation. *J. Biol. Chem.* **2011**, *286*, 41963–41971. [[CrossRef](#)]
11. Purcell, D.J.; Khalid, O.; Ou, C.Y.; Little, G.H.; Frenkel, B.; Baniwal, S.K.; Stallcup, M.R. Recruitment of Coregulator G9a by Runx2 for Selective Enhancement or Suppression of Transcription. *J. Cell. Biochem.* **2012**, *113*, 2406–2414. [[CrossRef](#)] [[PubMed](#)]
12. Chaturvedi, C.P.; Hosey, A.M.; Palii, C.; Perez-Iratxeta, C.; Nakatani, Y.; Ranish, J.A.; Dilworth, F.J.; Brand, M. Dual Role for the Methyltransferase G9a in the Maintenance of β -Globin Gene Transcription in Adult Erythroid Cells. *Proc. Natl. Acad. Sci. USA* **2009**, *106*, 18303–18308. [[CrossRef](#)] [[PubMed](#)]
13. Mauger, O.; Klinck, R.; Chabot, B.; Muchardt, C.; Allemand, E.; Batschébatsch 'batsché, E. Alternative Splicing Regulates the Expression of G9a and SUV39H2 Methyltransferases, and Dramatically Changes SUV39H2 Functions. *Nucleic Acids Res.* **2015**, *43*, 1869–1882. [[CrossRef](#)]
14. Fiszbein, A.; Giono, L.E.; Quaglino, A.; Berardino, B.G.; Sigaut, L.; von Bilderling, C.; Schor, I.E.; Steinberg, J.H.E.; Rossi, M.; Pietrasanta, L.I.; et al. Alternative Splicing of G9a Regulates Neuronal Differentiation. *Cell Rep.* **2016**, *14*, 2797–2808. [[CrossRef](#)]
15. Shankar, S.R.; Bahirvani, A.G.; Rao, V.K.; Bharathy, N.; Ow, J.R.; Taneja, R. G9a, a Multipotent Regulator of Gene Expression. *Epigenetics* **2013**, *8*, 16–22. [[CrossRef](#)] [[PubMed](#)]
16. Schotta, G.; Ebert, A.; Krauss, V.; Fischer, A.; Hoffmann, J.; Rea, S.; Jenuwein, T.; Dorn, R.; Reuter, G. Central Role of Drosophila SU(VAR)3–9 in Histone H3-K9 Methylation and Heterochromatic Gene Silencing. *EMBO J.* **2002**, *21*, 1121–1131. [[CrossRef](#)]
17. Jenuwein, T.; Laible, G.; Dorn, R.; Reuter, G. SET Domain Proteins Modulate Chromatin Domains in Eu- and Heterochromatin. *Cell. Mol. Life Sci* **1998**, *54*, 80–93. [[CrossRef](#)]
18. Taylor, W.R.; Xiao, B.; Gamblin, S.J.; Lin, K. A Knot or Not a Knot? SETting the Record 'Straight' on Proteins. *Comput. Biol. Chem.* **2003**, *27*, 11–15. [[CrossRef](#)]
19. Trievel, R.C.; Beach, B.M.; Dirk, L.M.A.; Houtz, R.L.; Hurley, J.H. Structure and Catalytic Mechanism of a SET Domain Protein Methyltransferase. *Cell* **2002**, *111*, 91–103. [[CrossRef](#)]
20. Qian, C.; Zhou, M.M. SET Domain Protein Lysine Methyltransferases: Structure, Specificity and Catalysis. *Cell. Mol. Life Sci.* **2006**, *63*, 2755–2763. [[CrossRef](#)] [[PubMed](#)]
21. Wu, H.; Min, J.; Lunin, V.V.; Antoshenko, T.; Dombrowski, L.; Zeng, H.; Allali-Hassani, A.; Campagna-Slater, V.; Vedadi, M.; Arrowsmith, C.H.; et al. Structural Biology of Human H3K9 Methyltransferases. *PLoS ONE* **2010**, *5*, e8570. [[CrossRef](#)]
22. Lenstra, D.C.; al Temimi, A.H.K.; Mecinović, J. Inhibition of Histone Lysine Methyltransferases G9a and GLP by Ejection of Structural Zn(II). *Bioorganic Med. Chem. Lett.* **2018**, *28*, 1234–1238. [[CrossRef](#)]
23. Schapira, M. Structural Chemistry of Human SET Domain Protein Methyltransferases. *Curr. Chem. Genom.* **2011**, *5*, 85–94. [[CrossRef](#)]
24. Collins, R.E.; Northrop, J.P.; Horton, J.R.; Lee, D.Y.; Zhang, X.; Stallcup, M.R.; Cheng, X. The Ankyrin Repeats of G9a and GLP Histone Methyltransferases Are Mono- and Dimethyllysine Binding Modules. *Nat. Struct. Mol. Biol.* **2008**, *15*, 245–250. [[CrossRef](#)]
25. Estève, P.O.; Patnaik, D.; Chin, H.G.; Benner, J.; Teitell, M.A.; Pradhan, S. Functional Analysis of the N- and C-Terminus of Mammalian G9a Histone H3 Methyltransferase. *Nucleic Acids Res.* **2005**, *33*, 3211–3223. [[CrossRef](#)] [[PubMed](#)]
26. Corpet, F. Multiple Sequence Alignment with Hierarchical Clustering. *Nucleic Acids Res.* **1988**, *16*, 10881. [[CrossRef](#)] [[PubMed](#)]

27. Chang, Y.; Zhang, X.; Horton, J.R.; Upadhyay, A.K.; Spannhoff, A.; Liu, J.; Snyder, J.P.; Bedford, M.T.; Cheng, X. Structural Basis for G9a-like Protein Lysine Methyltransferase Inhibition by BIX-01294. *Nat. Struct. Mol. Biol.* **2009**, *16*, 312–317. [[CrossRef](#)]
28. Liu, N.; Zhang, Z.; Wu, H.; Jiang, Y.; Meng, L.; Xiong, J.; Zhao, Z.; Zhou, X.; Li, J.; Li, H.; et al. Recognition of H3K9 Methylation by GLP Is Required for Efficient Establishment of H3K9 Methylation, Rapid Target Gene Repression, and Mouse Viability. *Genes Dev.* **2015**, *29*, 379–393. [[CrossRef](#)]
29. Shinkai, Y.; Tachibana, M. H3K9 Methyltransferase G9a and the Related Molecule GLP. *Genes Dev.* **2011**, *25*, 781–788. [[CrossRef](#)] [[PubMed](#)]
30. Ueda, J.; Tachibana, M.; Ikura, T.; Shinkai, Y. Zinc Finger Protein Wiz Links G9a/GLP Histone Methyltransferases to the Co-Repressor Molecule CtBP. *J. Biol. Chem.* **2006**, *281*, 20120–20128. [[CrossRef](#)]
31. Bian, C.; Chen, Q.; Yu, X. The Zinc Finger Proteins ZNF644 and WIZ Regulate the G9A/GLP Complex for Gene Repression. *eLife* **2015**, *4*, e05606. [[CrossRef](#)] [[PubMed](#)]
32. Poulard, C.; Bittencourt, D.; Wu, D.; Hu, Y.; Gerke, D.S.; Stallcup, M.R. A Post-translational Modification Switch Controls Coactivator Function of Histone Methyltransferases G9a and GLP. *EMBO Rep.* **2017**, *18*, 1442–1459. [[CrossRef](#)] [[PubMed](#)]
33. Chin, H.G.; Pradhan, M.; Estève, P.O.; Patnaik, D.; Evans, T.C.; Pradhan, S. Sequence Specificity and Role of Proximal Amino Acids of the Histone H3 Tail on Catalysis of Murine G9a Lysine 9 Histone H3 Methyltransferase. *Biochemistry* **2005**, *44*, 12998–13006. [[CrossRef](#)] [[PubMed](#)]
34. Chin, H.G.; Estève, P.O.; Pradhan, M.; Benner, J.; Patnaik, D.; Carey, M.F.; Pradhan, S. Automethylation of G9a and Its Implication in Wider Substrate Specificity and HP1 Binding. *Nucleic Acids Res.* **2007**, *35*, 7313–7323. [[CrossRef](#)] [[PubMed](#)]
35. Sampath, S.C.; Marazzi, I.; Yap, K.L.; Sampath, S.C.; Krutchinsky, A.N.; Mecklenbräuker, I.; Viale, A.; Rudensky, E.; Zhou, M.M.; Chait, B.T.; et al. Methylation of a Histone Mimic within the Histone Methyltransferase G9a Regulates Protein Complex Assembly. *Mol. Cell* **2007**, *27*, 596–608. [[CrossRef](#)] [[PubMed](#)]
36. Rathert, P.; Dhayalan, A.; Murakami, M.; Zhang, X.; Tamas, R.; Jurkowska, R.; Komatsu, Y.; Shinkai, Y.; Cheng, X.; Jeltsch, A. Protein Lysine Methyltransferase G9a Acts on Non-Histone Targets. *Nat. Chem. Biol.* **2008**, *4*, 344–346. [[CrossRef](#)]
37. Patnaik, D.; Hang, G.C.; Estève, P.O.; Benner, J.; Jacobsen, S.E.; Pradhan, S. Substrate Specificity and Kinetic Mechanism of Mammalian G9a Histone H3 Methyltransferase. *J. Biol. Chem.* **2004**, *279*, 53248–53258. [[CrossRef](#)]
38. Fischle, W.; Tseng, B.S.; Dormann, H.L.; Ueberheide, B.M.; Garcia, B.A.; Shabanowitz, J.; Hunt, D.F.; Funabiki, H.; Allis, C.D. Regulation of HP1–Chromatin Binding by Histone H3 Methylation and Phosphorylation. *Nature* **2005**, *438*, 1116–1122. [[CrossRef](#)] [[PubMed](#)]
39. Hirota, T.; Lipp, J.J.; Toh, B.-H.; Peters, J.-M. Histone H3 Serine 10 Phosphorylation by Aurora B Causes HP1 Dissociation from Heterochromatin. *Nature* **2005**, *438*, 1176–1180. [[CrossRef](#)]
40. Poulard, C.; Baulu, E.; Lee, B.H.; Pufall, M.A.; Stallcup, M.R. Increasing G9a Automethylation Sensitizes B Acute Lymphoblastic Leukemia Cells to Glucocorticoid-Induced Death. *Cell Death Dis.* **2018**, *9*, 1–13. [[CrossRef](#)]
41. Ginjala, V.; Rodriguez-Colon, L.; Ganguly, B.; Gangidi, P.; Gallina, P.; Al-Hraishawi, H.; Kulkarni, A.; Tang, J.; Gheeya, J.; Simhadri, S.; et al. Protein-Lysine Methyltransferases G9a and GLP1 Promote Responses to DNA Damage. *Sci. Rep.* **2017**, *7*, 1–12. [[CrossRef](#)]
42. Yang, Q.; Zhu, Q.; Lu, X.; Du, Y.; Cao, L.; Shen, C.; Hou, T.; Li, M.; Li, Z.; Liu, C.; et al. G9a Coordinates with the RPA Complex to Promote DNA Damage Repair and Cell Survival. *Proc. Natl. Acad. Sci. USA* **2017**, *114*, E6054–E6063. [[CrossRef](#)]
43. Srinivasan, S.; Shankar, S.R.; Wang, Y.; Taneja, R. SUMOylation of G9a Regulates Its Function as an Activator of Myoblast Proliferation. *Cell Death Dis.* **2019**, *10*, 1–15. [[CrossRef](#)]
44. Casciello, F.; Al-Ejeh, F.; Kelly, G.; Brennan, D.J.; Ngiow, S.F.; Young, A.; Stoll, T.; Windloch, K.; Hill, M.M.; Smyth, M.J.; et al. G9a Drives Hypoxia-Mediated Gene Repression for Breast Cancer Cell Survival and Tumorigenesis. *Proc. Natl. Acad. Sci. USA* **2017**, *114*, 7077–7082. [[CrossRef](#)]
45. Kang, J.; Shin, S.H.; Yoon, H.; Huh, J.; Shin, H.W.; Chun, Y.S.; Park, J.W. FIH Is an Oxygen Sensor in Ovarian Cancer for G9a/GLP-Driven Epigenetic Regulation of Metastasis-Related Genes. *Cancer Res.* **2018**, *78*, 1184–1199. [[CrossRef](#)] [[PubMed](#)]
46. Tachibana, M.; Sugimoto, K.; Fukushima, T.; Shinkai, Y. SET Domain-Containing Protein, G9a, Is a Novel Lysine-Preferring Mammalian Histone Methyltransferase with Hyperactivity and Specific Selectivity to Lysines 9 and 27 of Histone H3. *J. Biol. Chem.* **2001**, *276*, 25309–25317. [[CrossRef](#)]
47. Richards, E.J.; Elgin, S.C.R. Epigenetic Codes for Heterochromatin Formation and Silencing: Rounding up the Usual Suspects. *Cell* **2002**, *108*, 489–500. [[CrossRef](#)]
48. Wu, H.; Chen, X.; Xiong, J.; Li, Y.; Li, H.; Ding, X.; Liu, S.; Chen, S.; Gao, S.; Zhu, B. Histone Methyltransferase G9a Contributes to H3K27 Methylation in vivo. *Cell Res.* **2011**, *21*, 365–367. [[CrossRef](#)] [[PubMed](#)]
49. Yu, Y.; Song, C.; Zhang, Q.; DiMaggio, P.A.; Garcia, B.A.; York, A.; Carey, M.F.; Grunstein, M. Histone H3 Lysine 56 Methylation Regulates DNA Replication through Its Interaction with PCNA. *Mol. Cell* **2012**, *46*, 7–17. [[CrossRef](#)]
50. Trojer, P.; Zhang, J.; Yonezawa, M.; Schmidt, A.; Zheng, H.; Jenuwein, T.; Reinberg, D. Dynamic Histone H1 Isoform 4 Methylation and Demethylation by Histone Lysine Methyltransferase G9a/KMT1C and the Jumonji Domain-Containing JMJD2/KDM4 Proteins. *J. Biol. Chem.* **2009**, *284*, 8395–8405. [[CrossRef](#)]
51. Weiss, T.; Hergeth, S.; Zeissler, U.; Izzo, A.; Tropberger, P.; Zee, B.M.; Dunder, M.; Garcia, B.A.; Daujat, S.; Schneider, R. Histone H1 Variant-Specific Lysine Methylation by G9a/KMT1C and G9a/KMT1D. *Epigenetics Chromatin* **2010**, *3*, 1–13. [[CrossRef](#)]
52. Cao, H.; Li, L.; Deying, Y.; Liming, Z.; Yewei, X.; Yu, B.; Liao, G.; Chen, J. Recent Progress in Histone Methyltransferase (G9a) Inhibitors as Anticancer Agents. *Eur. J. Med. Chem.* **2019**, *179*, 537–546. [[CrossRef](#)]

53. Xiong, Y.; Li, F.; Babault, N.; Wu, H.; Dong, A.; Zeng, H.; Chen, X.; Arrowsmith, C.H.; Brown, P.J.; Liu, J.; et al. Structure-Activity Relationship Studies of G9a-like Protein (GLP) Inhibitors. *Bioorg. Med. Chem.* **2017**, *25*, 4414–4423. [[CrossRef](#)]
54. Pless, O.; Kowenz-Leutz, E.; Knoblich, M.; Lausen, J.; Beyermann, M.; Walsh, M.J.; Leutz, A. G9a-Mediated Lysine Methylation Alters the Function of CCAAT/Enhancer-Binding Protein- β . *J. Biol. Chem.* **2008**, *283*, 26357–26363. [[CrossRef](#)]
55. Ling, B.M.T.; Bharathy, N.; Chung, T.-K.; Kok, W.K.; Li, S.; Tan, Y.H.; Rao, V.K.; Gopinadhan, S.; Sartorelli, V.; Walsh, M.J.; et al. Lysine Methyltransferase G9a Methylates the Transcription Factor MyoD and Regulates Skeletal Muscle Differentiation. *Proc. Natl. Acad. Sci. USA* **2012**, *109*, 841–846. [[CrossRef](#)] [[PubMed](#)]
56. Choi, J.; Jang, H.; Kim, H.; Lee, J.H.; Kim, S.T.; Cho, E.J.; Youn, H.D. Modulation of Lysine Methylation in Myocyte Enhancer Factor 2 during Skeletal Muscle Cell Differentiation. *Nucleic Acids Res.* **2014**, *42*, 224–234. [[CrossRef](#)] [[PubMed](#)]
57. Huang, J.; Dorsey, J.; Chuikov, S.; Zhang, X.; Jenuwein, T.; Reinberg, D.; Berger, S.L. G9a and G9L Methylate Lysine 373 in the Tumor Suppressor P53. *J. Biol. Chem.* **2010**, *285*, 9636–9641. [[CrossRef](#)] [[PubMed](#)]
58. Zhang, X.; Peng, D.; Xi, Y.; Yuan, C.; Sagum, C.A.; Klein, B.J.; Tanaka, K.; Wen, H.; Kutateladze, T.G.; Li, W.; et al. G9a-Mediated Methylation of ER α Links the PHF20/MOF Histone Acetyltransferase Complex to Hormonal Gene Expression. *Nat. Commun.* **2016**, *7*, 1–12. [[CrossRef](#)] [[PubMed](#)]
59. Chae, Y.C.; Kim, J.Y.; Park, J.W.; Kim, K.B.; Oh, H.; Lee, K.H.; Seo, S.B. FOXO1 Degradation via G9a-Mediated Methylation Promotes Cell Proliferation in Colon Cancer. *Nucleic Acids Res.* **2019**, *47*, 1692–1705. [[CrossRef](#)] [[PubMed](#)]
60. Moore, K.E.; Carlson, S.M.; Camp, N.D.; Cheung, P.; James, R.G.; Chua, K.F.; Wolf-Yadlin, A.; Gozani, O. A General Molecular Affinity Strategy for Global Detection and Proteomic Analysis of Lysine Methylation. *Mol. Cell* **2013**, *50*, 444–456. [[CrossRef](#)]
61. Lee, J.S.; Kim, Y.; Bhin, J.; Shin, H.-J.R.; Nam, H.J.; Lee, H.; Yoon, J.-B.; Binda, O.; Hwang, D.; Baek, S.H. Hypoxia-Induced Methylation of a Pontin Chromatin Remodeling Factor. *Proc. Natl. Acad. Sci. USA* **2011**, *108*, 13510–13515. [[CrossRef](#)] [[PubMed](#)]
62. Lee, J.S.; Kim, Y.; Kim, I.S.; Kim, B.; Choi, H.J.; Lee, J.M.; Shin, H.J.R.; Kim, J.H.; Kim, J.Y.; Seo, S.B.; et al. Negative Regulation of Hypoxic Responses via Induced Reptin Methylation. *Mol. Cell* **2010**, *39*, 71–85. [[CrossRef](#)] [[PubMed](#)]
63. Bao, L.; Chen, Y.; Lai, H.T.; Wu, S.Y.; Wang, J.E.; Hatanpaa, K.J.; Raisanen, J.M.; Fontenot, M.; Lega, B.; Chiang, C.M.; et al. Methylation of Hypoxia-Inducible Factor (HIF)-1 α by G9a/GLP Inhibits HIF-1 Transcriptional Activity and Cell Migration. *Nucleic Acids Res.* **2018**, *46*, 6576–6591. [[CrossRef](#)] [[PubMed](#)]
64. Nair, S.S.; Li, D.Q.; Kumar, R. A Core Chromatin Remodeling Factor Instructs Global Chromatin Signaling through Multivalent Reading of Nucleosome Codes. *Mol. Cell* **2013**, *49*, 704–718. [[CrossRef](#)]
65. Tsusaka, T.; Kikuchi, M.; Shimazu, T.; Suzuki, T.; Sohtome, Y.; Akakabe, M.; Sodeoka, M.; Dohmae, N.; Umehara, T.; Shinkai, Y. Tri-Methylation of ATF7IP by G9a/GLP Recruits the Chromodomain Protein MPP8. *Epigenetics Chromatin* **2018**, *11*, 1–16. [[CrossRef](#)]
66. Chang, Y.; Sun, L.; Kokura, K.; Horton, J.R.; Fukuda, M.; Espejo, A.; Izumi, V.; Koomen, J.M.; Bedford, M.T.; Zhang, X.; et al. MPP8 Mediates the Interactions between DNA Methyltransferase Dnmt3a and H3K9 Methyltransferase GLP/G9a. *Nat. Commun.* **2011**, *2*, 1–10. [[CrossRef](#)]
67. Watanabe, S.; Iimori, M.; Chan, D.V.; Hara, E.; Kitao, H.; Maehara, Y. MDC1 Methylation Mediated by Lysine Methyltransferases EHMT1 and EHMT2 Regulates Active ATM Accumulation Flanking DNA Damage Sites. *Sci. Rep.* **2018**, *8*, 1–10. [[CrossRef](#)]
68. Li, W.; Wang, H.-Y.; Zhao, X.; Duan, H.; Cheng, B.; Liu, Y.; Zhao, M.; Shu, W.; Mei, Y.; Wen, Z.; et al. A Methylation-Phosphorylation Switch Determines Plk1 Kinase Activity and Function in DNA Damage Repair. *Sci. Adv.* **2019**, *5*, eaau7566. [[CrossRef](#)]
69. Ferry, L.; Fournier, A.; Tsusaka, T.; Adelmant, G.; Shimazu, T.; Matano, S.; Kirsh, O.; Amouroux, R.; Dohmae, N.; Suzuki, T.; et al. Methylation of DNA Ligase 1 by G9a/GLP Recruits UHRF1 to Replicating DNA and Regulates DNA Methylation. *Mol. Cell* **2017**, *67*, 550–565. [[CrossRef](#)]
70. Kubicek, S.; O'Sullivan, R.J.; August, E.M.; Hickey, E.R.; Zhang, Q.; Teodoro, M.L.L.; Rea, S.; Mechtler, K.; Kowalski, J.A.; Homon, C.A.; et al. Reversal of H3K9me2 by a Small-Molecule Inhibitor for the G9a Histone Methyltransferase. *Mol. Cell* **2007**, *25*, 473–481. [[CrossRef](#)]
71. Liu, F.; Chen, X.; Allali-Hassani, A.; Quinn, A.M.; Wasney, G.A.; Dong, A.; Barsyte, D.; Kozieradzki, I.; Senisterra, G.; Chau, I.; et al. Discovery of a 2,4-Diamino-7-Aminoalkoxyquinazoline as a Potent and Selective Inhibitor of Histone Lysine Methyltransferase G9a. *J. Med. Chem.* **2009**, *52*, 7950–7953. [[CrossRef](#)] [[PubMed](#)]
72. Vedadi, M.; Barsyte-Lovejoy, D.; Liu, F.; Rival-Gervier, S.; Allali-Hassani, A.; Labrie, V.; Wigle, T.J.; DiMaggio, P.A.; Wasney, G.A.; Sierheyeva, A.; et al. A Chemical Probe Selectively Inhibits G9a and GLP Methyltransferase Activity in Cells. *Nat. Chem. Biol.* **2011**, *7*, 566–574. [[CrossRef](#)] [[PubMed](#)]
73. Milite, C.; Feoli, A.; Horton, J.R.; Rescigno, D.; Cipriano, A.; Pisapia, V.; Viviano, M.; Pepe, G.; Amendola, G.; Novellino, E.; et al. Discovery of a Novel Chemotype of Histone Lysine Methyltransferase EHMT1/2 (GLP/G9a) Inhibitors: Rational Design, Synthesis, Biological Evaluation, and Co-Crystal Structure. *J. Med. Chem.* **2019**, *62*, 2666–2689. [[CrossRef](#)] [[PubMed](#)]
74. Yuan, Y.; Wang, Q.; Paulk, J.; Kubicek, S.; Kemp, M.M.; Adams, D.J.; Shamji, A.F.; Wagner, B.K.; Schreiber, S.L. A Small-Molecule Probe of the Histone Methyltransferase G9a Induces Cellular Senescence in Pancreatic Adenocarcinoma. *ACS Chem. Biol.* **2012**, *7*, 1152–1157. [[CrossRef](#)] [[PubMed](#)]
75. Nishio, H.; Walsh, M.J. CCAAT Displacement Protein/Cut Homolog Recruits G9a Histone Lysine Methyltransferase to Repress Transcription. *Proc. Natl. Acad. Sci. USA* **2004**, *101*, 11257–11262. [[CrossRef](#)]

76. Duan, Z.; Zarebski, A.; Montoya-Durango, D.; Grimes, H.L.; Horwitz, M. Gfi1 Coordinates Epigenetic Repression of *P21^{Cip/WAF1}* by Recruitment of Histone Lysine Methyltransferase G9a and Histone Deacetylase 1. *Mol. Cell. Biol.* **2005**, *25*, 10338–10351. [[CrossRef](#)]
77. Györy, I.; Wu, J.; Fejér, G.; Seto, E.; Wright, K.L. PRDI-BF1 Recruits the Histone H3 Methyltransferase G9a in Transcriptional Silencing. *Nat. Immunol.* **2004**, *5*, 299–308. [[CrossRef](#)]
78. Roopra, A.; Qazi, R.; Schoenike, B.; Daley, T.J.; Morrison, J.F. Localized Domains of G9a-Mediated Histone Methylation Are Required for Silencing of Neuronal Genes. *Mol. Cell* **2004**, *14*, 727–738. [[CrossRef](#)]
79. Kim, J.K.; Estève, P.O.; Jacobsen, S.E.; Pradhan, S. UHRF1 Binds G9a and Participates in P21 Transcriptional Regulation in Mammalian Cells. *Nucleic Acids Res.* **2009**, *37*, 493–505. [[CrossRef](#)]
80. Nagano, T.; Mitchell, J.A.; Sanz, L.A.; Pauler, F.M.; Ferguson-Smith, A.C.; Feil, R.; Fraser, P. The Air Noncoding RNA Epigenetically Silences Transcription by Targeting G9a to Chromatin. *Science* **2008**, *322*, 1717–1720. [[CrossRef](#)]
81. Mozzetta, C.; Pontis, J.; Fritsch, L.; Robin, P.; Portoso, M.; Proux, C.; Margueron, R.; Ait-Si-Ali, S. The Histone H3 Lysine 9 Methyltransferases G9a and GLP Regulate Polycomb Repressive Complex 2-Mediated Gene Silencing. *Mol. Cell* **2014**, *53*, 277–289. [[CrossRef](#)] [[PubMed](#)]
82. Lomber, G.; Wallrath, L.; Urrutia, R. The Heterochromatin Protein 1 Family. *Genome Biol.* **2006**, *7*, 1–8. [[CrossRef](#)] [[PubMed](#)]
83. Fritsch, L.; Robin, P.; Mathieu, J.R.R.; Souidi, M.; Hinaux, H.; Rougeulle, C.; Harel-Bellan, A.; Ameyar-Zazoua, M.; Ait-Si-Ali, S. A Subset of the Histone H3 Lysine 9 Methyltransferases Suv39h1, G9a, GLP, and SETDB1 Participate in a Multimeric Complex. *Mol. Cell* **2010**, *37*, 46–56. [[CrossRef](#)] [[PubMed](#)]
84. Epsztejn-Litman, S.; Feldman, N.; Abu-Remaileh, M.; Shufaro, Y.; Gerson, A.; Ueda, J.; Deplus, R.; Fuks, F.; Shinkai, Y.; Cedar, H.; et al. De Novo DNA Methylation Promoted by G9a Prevents Reprogramming of Embryonically Silenced Genes. *Nat. Struct. Mol. Biol.* **2008**, *15*, 1176–1183. [[CrossRef](#)] [[PubMed](#)]
85. Bittencourt, D.; Lee, B.H.; Gao, L.; Gerke, D.S.; Stallcup, M.R. Role of Distinct Surfaces of the G9a Ankyrin Repeat Domain in Histone and DNA Methylation during Embryonic Stem Cell Self-Renewal and Differentiation. *Epigenetics Chromatin* **2014**, *7*, 1–12. [[CrossRef](#)]
86. Smallwood, A.; Estève, P.O.; Pradhan, S.; Carey, M. Functional Cooperation between HP1 and DNMT1 Mediates Gene Silencing. *Genes Dev.* **2007**, *21*, 1169–1178. [[CrossRef](#)] [[PubMed](#)]
87. Oh, S.T.; Kim, K.B.; Chae, Y.C.; Kang, J.Y.; Hahn, Y.; Seo, S.B. H3K9 Histone Methyltransferase G9a-Mediated Transcriptional Activation of P21. *FEBS Lett.* **2014**, *588*, 685–691. [[CrossRef](#)]
88. Poulard, C.; Kim, H.N.; Fang, M.; Kruth, K.; Gagnieux, C.; Gerke, D.S.; Bhojwani, D.; Kim, Y.M.; Kampmann, M.; Stallcup, M.R.; et al. Relapse-Associated AURKB Blunts the Glucocorticoid Sensitivity of B Cell Acute Lymphoblastic Leukemia. *Proc. Natl. Acad. Sci. USA* **2019**, *116*, 3052–3061. [[CrossRef](#)]
89. Chaturvedi, C.P.; Somasundaram, B.; Singh, K.; Carpenedo, R.L.; Stanford, W.L.; Dilworth, F.J.; Brand, M. Maintenance of Gene Silencing by the Coordinate Action of the H3K9 Methyltransferase G9a/KMT1C and the H3K4 Demethylase Jarid1a/KDM5A. *Proc. Natl. Acad. Sci. USA* **2012**, *109*, 18845–18850. [[CrossRef](#)]
90. Tachibana, M.; Nozaki, M.; Takeda, N.; Shinkai, Y. Functional Dynamics of H3K9 Methylation during Meiotic Prophase Progression. *EMBO J.* **2007**, *26*, 3346–3359. [[CrossRef](#)]
91. Inagawa, M.; Nakajima, K.; Makino, T.; Ogawa, S.; Kojima, M.; Ito, S.; Ikenishi, A.; Hayashi, T.; Schwartz, R.J.; Nakamura, K.; et al. Histone H3 Lysine 9 Methyltransferases, G9a and GLP Are Essential for Cardiac Morphogenesis. *Mech. Dev.* **2013**, *130*, 519–531. [[CrossRef](#)] [[PubMed](#)]
92. Schaefer, A.; Sampath, S.C.; Intrator, A.; Min, A.; Gertler, T.S.; Surmeier, D.J.; Tarakhovskiy, A.; Greengard, P. Control of Cognition and Adaptive Behavior by the GLP/G9a Epigenetic Suppressor Complex. *Neuron* **2009**, *64*, 678–691. [[CrossRef](#)] [[PubMed](#)]
93. Nicolay-Kritter, K.; Lassalle, J.; Guillou, J.L.; Mons, N. The Histone H3 Lysine 9 Methyltransferase G9a/GLP Complex Activity Is Required for Long-Term Consolidation of Spatial Memory in Mice. *Neurobiol. Learn. Mem.* **2021**, *179*, 107406. [[CrossRef](#)]
94. Maze, I.; Covington, H.E.; Dietz, D.M.; LaPlant, Q.; Renthal, W.; Russo, S.J.; Mechanic, M.; Mouzon, E.; Neve, R.L.; Haggarty, S.J.; et al. Essential Role of the Histone Methyltransferase G9a in Cocaine-Induced Plasticity. *Science* **2010**, *327*, 213–216. [[CrossRef](#)]
95. Maze, I.; Chaudhury, D.; Dietz, D.M.; von Schimmelmann, M.; Kennedy, P.J.; Lobo, M.K.; Sullivan, S.E.; Miller, M.L.; Bagot, R.C.; Sun, H.; et al. G9a Influences Neuronal Subtype Specification in Striatum. *Nat. Neurosci.* **2014**, *17*, 533–539. [[CrossRef](#)] [[PubMed](#)]
96. Kamiunten, T.; Ideno, H.; Shimada, A.; Arai, Y.; Terashima, T.; Tomooka, Y.; Nakamura, Y.; Nakashima, K.; Kimura, H.; Shinkai, Y.; et al. Essential Roles of G9a in Cell Proliferation and Differentiation during Tooth Development. *Exp. Cell Res.* **2017**, *357*, 202–210. [[CrossRef](#)]
97. Ideno, H.; Nakashima, K.; Komatsu, K.; Araki, R.; Abe, M.; Arai, Y.; Kimura, H.; Shinkai, Y.; Tachibana, M.; Nifuji, A. G9a Is Involved in the Regulation of Cranial Bone Formation through Activation of Runx2 Function during Development. *Bone* **2020**, *137*, 115332. [[CrossRef](#)] [[PubMed](#)]
98. Higashihori, N.; Lehnertz, B.; Sampaio, A.; Underhill, T.M.; Rossi, F.; Richman, J.M. Methyltransferase G9A Regulates Osteogenesis via Twist Gene Repression. *J. Dent. Res.* **2017**, *96*, 1136–1144. [[CrossRef](#)]
99. Komori, T. Regulation of Proliferation, Differentiation and Functions of Osteoblasts by Runx2. *Int. J. Mol. Sci.* **2019**, *20*, 1694. [[CrossRef](#)]
100. Zhang, R.H.; Judson, R.N.; Liu, D.Y.; Kast, J.; Rossi, F.M.V. The Lysine Methyltransferase Ehmt2/G9a Is Dispensable for Skeletal Muscle Development and Regeneration. *Skelet. Muscle* **2016**, *6*, 1–10. [[CrossRef](#)]

101. Katoh, K.; Yamazaki, R.; Onishi, A.; Sanuki, R.; Furukawa, T. G9a Histone Methyltransferase Activity in Retinal Progenitors Is Essential for Proper Differentiation and Survival of Mouse Retinal Cells. *J. Neurosci.* **2012**, *32*, 17658–17670. [[CrossRef](#)]
102. Olsen, J.B.; Wong, L.; Deimling, S.; Miles, A.; Guo, H.; Li, Y.; Zhang, Z.; Greenblatt, J.F.; Emili, A.; Tropepe, V. G9a and ZNF644 Physically Associate to Suppress Progenitor Gene Expression during Neurogenesis. *Stem Cell Rep.* **2016**, *7*, 454–470. [[CrossRef](#)]
103. Chen, H.; Yan, Y.; Davidson, T.L.; Shinkai, Y.; Costa, M. Hypoxic Stress Induces Dimethylated Histone H3 Lysine 9 through Histone Methyltransferase G9a in Mammalian Cells. *Cancer Res.* **2006**, *66*, 9009–9016. [[CrossRef](#)]
104. Macürek, L.; Lindqvist, A.; Lim, D.; Lampson, M.A.; Klompaker, R.; Freire, R.; Clouin, C.; Taylor, S.S.; Yaffe, M.B.; Medema, R.H. Polo-like Kinase-1 Is Activated by Aurora A to Promote Checkpoint Recovery. *Nature* **2008**, *455*, 119–123. [[CrossRef](#)]
105. Agarwal, P.; Jackson, S.P. G9a Inhibition Potentiates the Anti-Tumour Activity of DNA Double-Strand Break Inducing Agents by Impairing DNA Repair Independent of P53 Status. *Cancer Lett.* **2016**, *380*, 467–475. [[CrossRef](#)]
106. Zhang, J.; Wang, Y.; Shen, Y.; He, P.; Ding, J.; Chen, Y. G9a Stimulates CRC Growth by Inducing P53 Lys373 Dimethylation-Dependent Activation of Plk1. *Theranostics* **2018**, *8*, 2884–2895. [[CrossRef](#)]
107. Sharma, S.; Kelly, T.K.; Jones, P.A. Epigenetics in Cancer. *Carcinogenesis* **2010**, *31*, 27–36. [[CrossRef](#)] [[PubMed](#)]
108. Campbell, M.J.; Turner, B.M. Altered Histone Modifications in Cancer. *Adv. Exp. Med. Biol.* **2013**, *754*, 81–107. [[CrossRef](#)] [[PubMed](#)]
109. Wang, Y.; Zhang, J.; Su, Y.; Shen, Y.; Jiang, D.; Hou, Y.; Geng, M.; Ding, J.; Chen, Y. G9a Regulates Breast Cancer Growth by Modulating Iron Homeostasis through the Repression of Ferroxidase Hephaestin. *Nat. Commun.* **2017**, *8*, 1–14. [[CrossRef](#)] [[PubMed](#)]
110. Chen, P.; Qian, Q.; Zhu, Z.; Shen, X.; Yu, S.; Yu, Z.; Sun, R.; Li, Y.; Guo, D.; Fan, H. Increased Expression of EHMT2 Associated with H3K9me2 Level Contributes to the Poor Prognosis of Gastric Cancer. *Oncol. Lett.* **2020**, *20*, 1734–1742. [[CrossRef](#)]
111. Hua, K.-T.; Wang, M.-Y.; Chen, M.-W.; Wei, L.-H.; Chen, C.-K.; Ko, C.-H.; Jeng, Y.-M.; Sung, P.-L.; Jan, Y.-H.; Hsiao, M.; et al. The H3K9 Methyltransferase G9a Is a Marker of Aggressive Ovarian Cancer That Promotes Peritoneal Metastasis. *Mol. Cancer* **2014**, *13*, 1–13. [[CrossRef](#)]
112. Chen, G.; Yu, X.; Zhang, M.; Zheng, A.; Wang, Z.; Zuo, Y.; Liang, Q.; Jiang, D.; Chen, Y.; Zhao, L.; et al. Inhibition of Euchromatic Histone Lysine Methyltransferase 2 (EHMT2) Suppresses the Proliferation and Invasion of Cervical Cancer Cells. *Cytogenet. Genome Res.* **2019**, *158*, 205–212. [[CrossRef](#)]
113. Hsiao, S.M.; Chen, M.W.; Chen, C.A.; Chien, M.H.; Hua, K.T.; Hsiao, M.; Kuo, M.L.; Wei, L.H. The H3K9 Methyltransferase G9a Represses E-Cadherin and Is Associated with Myometrial Invasion in Endometrial Cancer. *Ann. Surg. Oncol.* **2015**, *22*, 1556–1565. [[CrossRef](#)]
114. Fan, H.T.; Shi, Y.Y.; Lin, Y.; Yang, X.P. EHMT2 Promotes the Development of Prostate Cancer by Inhibiting PI3K/AKT/MTOR Pathway. *Eur. Rev. Med. Pharmacol. Sci.* **2019**, *23*, 7808–7815. [[CrossRef](#)]
115. Qin, J.; Zeng, Z.; Luo, T.; Li, Q.; Hao, Y.; Chen, L. Clinicopathological Significance of G9A Expression in Colorectal Carcinoma. *Oncol. Lett.* **2018**, *15*, 8611–8619. [[CrossRef](#)] [[PubMed](#)]
116. Wei, L.; Chiu, D.K.C.; Tsang, F.H.C.; Law, C.T.; Cheng, C.L.H.; Au, S.L.K.; Lee, J.M.F.; Wong, C.C.L.; Ng, I.O.L.; Wong, C.M. Histone Methyltransferase G9a Promotes Liver Cancer Development by Epigenetic Silencing of Tumor Suppressor Gene RARRES3. *J. Hepatol.* **2017**, *67*, 758–769. [[CrossRef](#)]
117. Guo, A.S.; Huang, Y.Q.; Ma, X.D.; Lin, R.S. Mechanism of G9a Inhibitor BIX-01294 Acting on U251 Glioma Cells. *Mol. Med. Rep.* **2016**, *14*, 4613–4621. [[CrossRef](#)] [[PubMed](#)]
118. Zhang, X.Y.; Rajagopalan, D.; Chung, T.H.; Hooi, L.; Toh, T.B.; Tian, J.S.; Rashid, M.B.M.A.; Sahib, N.R.B.M.; Gu, M.; Lim, J.J.; et al. Frequent Upregulation of G9a Promotes RelB-Dependent Proliferation and Survival in Multiple Myeloma. *Exp. Hematol. Oncol.* **2020**, *9*, 8. [[CrossRef](#)] [[PubMed](#)]
119. Dang, N.N.; Jiao, J.; Meng, X.; An, Y.; Han, C.; Huang, S. Abnormal Overexpression of G9a in Melanoma Cells Promotes Cancer Progression via Upregulation of the Notch1 Signaling Pathway. *Aging* **2020**, *12*, 2393–2407. [[CrossRef](#)]
120. Ma, W.; Han, C.; Zhang, J.; Song, K.; Chen, W.; Kwon, H.; Wu, T. The Histone Methyltransferase G9a Promotes Cholangiocarcinogenesis through Regulation of the Hippo Pathway Kinase LATS2 and YAP Signaling Pathway. *FASEB J.* **2020**, *34*, 1283–1297. [[CrossRef](#)]
121. Zhang, K.; Wang, J.; Yang, L.; Yuan, Y.-C.; Tong, T.R.; Wu, J.; Yun, X.; Bonner, M.; Pangeni, R.; Liu, Z.; et al. Targeting Histone Methyltransferase G9a Inhibits Growth and Wnt Signaling Pathway by Epigenetically Regulating HP1 α and APC2 Gene Expression in Non-Small Cell Lung Cancer. *Mol. Cancer* **2018**, *17*, 1–15. [[CrossRef](#)]
122. Cui, J.; Sun, W.; Hao, X.; Wei, M.; Su, X.; Zhang, Y.; Su, L.; Liu, X. EHMT2 Inhibitor BIX-01294 Induces Apoptosis through PMAIP1-USP9X-MCL1 Axis in Human Bladder Cancer Cells. *Cancer Cell Int.* **2015**, *15*, 1–9. [[CrossRef](#)]
123. Casciello, F.; Al-Ejeh, F.; Miranda, M.; Kelly, G.; Baxter, E.; Windloch, K.; Gannon, F.; Lee, J.S. G9a-Mediated Repression of CDH10 in Hypoxia Enhances Breast Tumour Cell Motility and Associates with Poor Survival Outcome. *Theranostics* **2020**, *10*, 4515–4529. [[CrossRef](#)]
124. Chen, M.-W.; Hua, K.-T.; Kao, H.-J.; Chi, C.-C.; Wei, L.-H.; Johansson, G.; Shiah, S.-G.; Chen, P.-S.; Jeng, Y.-M.; Cheng, T.-Y.; et al. H3K9 Histone Methyltransferase G9a Promotes Lung Cancer Invasion and Metastasis by Silencing the Cell Adhesion Molecule Ep-CAM. *Cancer Res.* **2010**, *70*, 7830–7840. [[CrossRef](#)]
125. Yin, C.; Ke, X.; Zhang, R.; Hou, J.; Dong, Z.; Wang, F.; Zhang, K.; Zhong, X.; Yang, L.; Cui, H. G9a Promotes Cell Proliferation and Suppresses Autophagy in Gastric Cancer by Directly Activating MTOR. *FASEB J.* **2019**, *33*, 14036–14050. [[CrossRef](#)]

126. Zhong, X.; Chen, X.; Guan, X.; Zhang, H.; Ma, Y.; Zhang, S.; Wang, E.; Zhang, L.; Han, Y. Overexpression of G9a and MCM7 in Oesophageal Squamous Cell Carcinoma Is Associated with Poor Prognosis. *Histopathology* **2015**, *66*, 192–200. [[CrossRef](#)]
127. Ho, J.C.; Abdullah, L.N.; Pang, Q.Y.; Jha, S.; Chow, E.K.H.; Yang, H.; Kato, H.; Poellinger, L.; Ueda, J.; Lee, K.L. Inhibition of the H3K9 Methyltransferase G9A Attenuates Oncogenicity and Activates the Hypoxia Signaling Pathway. *PLoS ONE* **2017**, *12*, e0188051. [[CrossRef](#)]
128. Liu, X.R.; Zhou, L.H.; Hu, J.X.; Liu, L.M.; Wan, H.P.; Zhang, X.Q. UNC0638, a G9a Inhibitor, Suppresses Epithelial-Mesenchymal Transition-Mediated Cellular Migration and Invasion in Triple Negative Breast Cancer. *Mol. Med. Rep.* **2018**, *17*, 2239–2244. [[CrossRef](#)] [[PubMed](#)]
129. Tu, W.B.; Shiah, Y.J.; Lourenco, C.; Mullen, P.J.; Dingar, D.; Redel, C.; Tamachi, A.; Ba-Alawi, W.; Aman, A.; Al-awar, R.; et al. MYC Interacts with the G9a Histone Methyltransferase to Drive Transcriptional Repression and Tumorigenesis. *Cancer Cell* **2018**, *34*, 579–595. [[CrossRef](#)] [[PubMed](#)]
130. Wozniak, R.J.; Klimecki, W.T.; Lau, S.S.; Feinstein, Y.; Futscher, B.W. 5-Aza-2'-Deoxycytidine-Mediated Reductions in G9A Histone Methyltransferase and Histone H3 K9 Di-Methylation Levels Are Linked to Tumor Suppressor Gene Reactivation. *Oncogene* **2007**, *26*, 77–90. [[CrossRef](#)] [[PubMed](#)]
131. Dong, C.; Wu, Y.; Yao, J.; Wang, Y.; Yu, Y.; Rychahou, P.G.; Evers, B.M.; Zhou, B.P. G9a Interacts with Snail and Is Critical for Snail-Mediated E-Cadherin Repression in Human Breast Cancer. *J. Clin. Investig.* **2012**, *122*, 1469–1486. [[CrossRef](#)] [[PubMed](#)]
132. Zhang, J.; Yao, D.; Jiang, Y.; Huang, J.; Yang, S.; Wang, J. Synthesis and Biological Evaluation of Benzimidazole Derivatives as the G9a Histone Methyltransferase Inhibitors That Induce Autophagy and Apoptosis of Breast Cancer Cells. *Bioorg. Chem.* **2017**, *72*, 168–181. [[CrossRef](#)]
133. Mabe, N.W.; Garcia, N.M.G.; Wolery, S.E.; Newcomb, R.; Meingasner, R.C.; Vilona, B.A.; Lupo, R.; Lin, C.C.; Chi, J.T.; Alvarez, J.V. G9a Promotes Breast Cancer Recurrence through Repression of a Pro-Inflammatory Program. *Cell Rep.* **2020**, *33*, 108341. [[CrossRef](#)]
134. Lin, X.; Huang, Y.; Zou, Y.; Chen, X.; Ma, X. Depletion of G9a Gene Induces Cell Apoptosis in Human Gastric Carcinoma. *Oncol. Rep.* **2016**, *35*, 3041–3049. [[CrossRef](#)] [[PubMed](#)]
135. Kim, T.W.; Lee, S.Y.; Kim, M.; Cheon, C.; Ko, S.-G. Kaempferol Induces Autophagic Cell Death via IRE1-JNK-CHOP Pathway and Inhibition of G9a in Gastric Cancer Cells. *Cell Death Dis.* **2018**, *9*, 1–14. [[CrossRef](#)]
136. Kim, T.W.; Cheon, C.; Ko, S.-G. SH003 Activates Autophagic Cell Death by Activating ATF4 and Inhibiting G9a under Hypoxia in Gastric Cancer Cells. *Cell Death Dis.* **2020**, *11*, 1–14. [[CrossRef](#)] [[PubMed](#)]
137. Kim, T.W. Cinnamaldehyde Induces Autophagy-Mediated Cell Death through ER Stress and Epigenetic Modification in Gastric Cancer Cells. *Acta Pharmacol. Sin.* **2021**, *2021*, 1–12. [[CrossRef](#)]
138. Lee, S.H.; Kim, J.; Kim, W.-H.; Lee, Y.M. Hypoxic Silencing of Tumor Suppressor RUNX3 by Histone Modification in Gastric Cancer Cells. *Oncogene* **2009**, *28*, 184–194. [[CrossRef](#)]
139. Hu, L.; Zang, M.; Wang, H.; Zhang, B.; Wang, Z.; Fan, Z.; Wu, H.; Li, J.; Su, L.; Yan, M.; et al. G9A Promotes Gastric Cancer Metastasis by Upregulating ITGB3 in a SET Domain-Independent Manner. *Cell Death Dis.* **2018**, *9*, 1–14. [[CrossRef](#)]
140. Watson, Z.L.; Yamamoto, T.M.; McMellen, A.; Kim, H.; Hughes, C.J.; Wheeler, L.J.; Post, M.D.; Behbakht, K.; Bitler, B.G. Histone Methyltransferases EHMT1 and EHMT2 (GLP/G9A) Maintain PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma. *Clin. Epigenetics* **2019**, *11*, 1–16. [[CrossRef](#)]
141. Liu, M.; Thomas, S.L.; DeWitt, A.K.; Zhou, W.; Madaj, Z.B.; Ohtani, H.; Baylin, S.B.; Liang, G.; Jones, P.A. Dual Inhibition of DNA and Histone Methyltransferases Increases Viral Mimicry in Ovarian Cancer Cells. *Cancer Res.* **2018**, *78*, 5754–5766. [[CrossRef](#)] [[PubMed](#)]
142. Chen, R.-J.; Shun, C.-T.; Yen, M.-L.; Chou, C.-H.; Lin, M.-C.; Chen, R.-J.; Shun, C.-T.; Yen, M.-L.; Chou, C.-H.; Lin, M.-C. Methyltransferase G9a Promotes Cervical Cancer Angiogenesis and Decreases Patient Survival. *Oncotarget* **2017**, *8*, 62081–62098. [[CrossRef](#)] [[PubMed](#)]
143. Watanabe, H.; Soejima, K.; Yasuda, H.; Kawada, I.; Nakachi, I.; Yoda, S.; Naoki, K.; Ishizaka, A. Dereglulation of Histone Lysine Methyltransferases Contributes to Oncogenic Transformation of Human Bronchoepithelial Cells. *Cancer Cell Int.* **2008**, *8*, 1–12. [[CrossRef](#)]
144. Huang, T.; Zhang, P.; Li, W.; Zhao, T.; Zhang, Z.; Chen, S.; Yang, Y.; Feng, Y.; Li, F.; Shirley Liu, X.; et al. G9A Promotes Tumor Cell Growth and Invasion by Silencing CASP1 in Non-Small-Cell Lung Cancer Cells. *Cell Death Dis.* **2017**, *8*, e2726. [[CrossRef](#)]
145. Hu, Y.; Zheng, Y.; Dai, M.; Wu, J.; Yu, B.; Zhang, H.; Kong, W.; Wu, H.; Yu, X. Snail2 Induced E-Cadherin Suppression and Metastasis in Lung Carcinoma Facilitated by G9a and HDACs. *Cell Adhes. Migr.* **2019**, *13*, 285–292. [[CrossRef](#)]
146. Sun, T.; Zhang, K.; Pangeni, R.P.; Wu, J.; Li, W.; Du, Y.; Guo, Y.; Chaurasiya, S.; Arvanitis, L.; Raz, D.J. G9a Promotes Invasion and Metastasis of Non-Small Cell Lung Cancer through Enhancing Focal Adhesion Kinase Activation via NF-KB Signaling Pathway. *Mol. Cancer Res.* **2021**, *19*, 429–440. [[CrossRef](#)] [[PubMed](#)]
147. Pangeni, R.P.; Yang, L.; Zhang, K.; Wang, J.; Li, W.; Guo, C.; Yun, X.; Sun, T.; Wang, J.; Raz, D.J. G9a Regulates Tumorigenicity and Stemness through Genome-Wide DNA Methylation Reprogramming in Non-Small Cell Lung Cancer. *Clin. Epigenetics* **2020**, *12*, 1–17. [[CrossRef](#)] [[PubMed](#)]
148. Bergin, C.J.; Zouggar, A.; Haebe, J.R.; Masibag, A.N.; Desrochers, F.M.; Reilley, S.Y.; Agrawal, G.; Benoit, Y.D. G9a Controls Pluripotent-like Identity and Tumor-Initiating Function in Human Colorectal Cancer. *Oncogene* **2020**, *40*, 1191–1202. [[CrossRef](#)]

149. Bárcena-Varela, M.; Caruso, S.; Llerena, S.; Álvarez-Sola, G.; Uriarte, I.; Latasa, M.U.; Urtasun, R.; Rebouissou, S.; Alvarez, L.; Jimenez, M.; et al. Dual Targeting of Histone Methyltransferase G9a and DNA-Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma. *Hepatology* **2019**, *69*, 587–603. [[CrossRef](#)]
150. Yokoyama, M.; Chiba, T.; Zen, Y.; Oshima, M.; Kusakabe, Y.; Noguchi, Y.; Yuki, K.; Koide, S.; Tara, S.; Saraya, A.; et al. Histone Lysine Methyltransferase G9a Is a Novel Epigenetic Target for the Treatment of Hepatocellular Carcinoma. *Oncotarget* **2017**, *8*, 21315–21326. [[CrossRef](#)]
151. Hu, Y.; Zheng, Y.; Dai, M.; Wang, X.; Wu, J.; Yu, B.; Zhang, H.; Cui, Y.; Kong, W.; Wu, H.; et al. G9a and Histone Deacetylases Are Crucial for Snail2-Mediated E-Cadherin Repression and Metastasis in Hepatocellular Carcinoma. *Cancer Sci.* **2019**, *110*, 3442–3452. [[CrossRef](#)]
152. Nakatsuka, T.; Tateishi, K.; Kato, H.; Fujiwara, H.; Yamamoto, K.; Kudo, Y.; Nakagawa, H.; Tanaka, Y.; Ijichi, H.; Ikenoue, T.; et al. Inhibition of Histone Methyltransferase G9a Attenuates Liver Cancer Initiation by Sensitizing DNA-Damaged Hepatocytes to P53-Induced Apoptosis. *Cell Death Dis.* **2021**, *12*, 1–13. [[CrossRef](#)]
153. Segovia, C.; San José-Enériz, E.; Munera-Maravilla, E.; Martínez-Fernández, M.; Garate, L.; Miranda, E.; Vilas-Zornoza, A.; Lodewijk, I.; Rubio, C.; Segrelles, C.; et al. Inhibition of a G9a/DNMT Network Triggers Immune-Mediated Bladder Cancer Regression. *Nat. Med.* **2019**, *25*, 1073–1081. [[CrossRef](#)] [[PubMed](#)]
154. Alves-Silva, J.C.; de Carvalho, J.L.; Rabello, D.A.; Serejo, T.R.T.; Rego, E.M.; Neves, F.A.R.; Lucena-Araujo, A.R.; Pittella-Silva, F.; Saldanha-Araujo, F. GLP Overexpression Is Associated with Poor Prognosis in Chronic Lymphocytic Leukemia and Its Inhibition Induces Leukemic Cell Death. *Investig. New Drugs* **2018**, *36*, 955–960. [[CrossRef](#)]
155. Huang, Y.; Zou, Y.; Lin, L.; Ma, X.; Huang, X. Effect of BIX-01294 on Proliferation, Apoptosis and Histone Methylation of Acute T Lymphoblastic Leukemia Cells. *Leuk. Res.* **2017**, *62*, 34–39. [[CrossRef](#)] [[PubMed](#)]
156. Kondengaden, S.M.; Luo, L.F.; Huang, K.; Zhu, M.; Zang, L.; Bataba, E.; Wang, R.; Luo, C.; Wang, B.; Li, K.K.; et al. Discovery of Novel Small Molecule Inhibitors of Lysine Methyltransferase G9a and Their Mechanism in Leukemia Cell Lines. *Eur. J. Med. Chem.* **2016**, *122*, 382–393. [[CrossRef](#)]
157. Lehnertz, B.; Pabst, C.; Su, L.; Miller, M.; Liu, F.; Yi, L.; Zhang, R.; Krosch, J.; Yung, E.; Kirschner, J.; et al. The Methyltransferase G9a Regulates HoxA9-Dependent Transcription in AML. *Genes Dev.* **2014**, *28*, 317–327. [[CrossRef](#)]
158. San José-Enériz, E.; Agirre, X.; Rabal, O.; Vilas-Zornoza, A.; Sanchez-Arias, J.A.; Miranda, E.; Ugarte, A.; Roa, S.; Paiva, B.; Estella-Hermoso de Mendoza, A.; et al. Discovery of First-in-Class Reversible Dual Small Molecule Inhibitors against G9a and DNMTs in Hematological Malignancies. *Nat. Commun.* **2017**, *8*, 1–10. [[CrossRef](#)]
159. Madrazo, E.; Ruano, D.; Abad, L.; Alonso-Gómez, E.; Sánchez-Valdepeñas, C.; González-Murillo, Á.; Ramírez, M.; Redondo-Muñoz, J. G9a Correlates with VLA-4 Integrin and Influences the Migration of Childhood Acute Lymphoblastic Leukemia Cells. *Cancers* **2018**, *10*, 325. [[CrossRef](#)]
160. Nagaraja, S.G.S.; Subramanian, U.; Nagarajan, D. Radiation-Induced H3K9 Methylation on E-Cadherin Promoter Mediated by ROS/Snail Axis: Role of G9a Signaling during Lung Epithelial-Mesenchymal Transition. *Toxicol. Vitro.* **2021**, *70*, 105037. [[CrossRef](#)] [[PubMed](#)]
161. Li, Y.; Chen, Z.; Cao, K.; Zhang, L.; Ma, Y.; Yu, S.; Jin, H.; Liu, X.; Li, W. G9a Regulates Cell Sensitivity to Radiotherapy via Histone H3 Lysine 9 Trimethylation and Ccdc8 in Lung Cancer. *OncoTargets Ther.* **2021**, *14*, 3721–3728. [[CrossRef](#)]
162. Luo, C.W.; Wang, J.Y.; Hung, W.C.; Peng, G.; Tsai, Y.L.; Chang, T.M.; Chai, C.Y.; Lin, C.H.; Pan, M.R. G9a Governs Colon Cancer Stem Cell Phenotype and Chemoradioresistance through PP2A-RPA Axis-Mediated DNA Damage Response. *Radiother. Oncol.* **2017**, *124*, 395–402. [[CrossRef](#)]
163. Dobson, T.H.W.; Hatcher, R.J.; Swaminathan, J.; Das, C.M.; Shaik, S.; Tao, R.-H.; Milite, C.; Castellano, S.; Taylor, P.H.; Sbardella, G.; et al. Regulation of USP37 Expression by REST-Associated G9a-Dependent Histone Methylation. *Mol. Cancer Res.* **2017**, *15*, 1073–1084. [[CrossRef](#)] [[PubMed](#)]
164. Ciechomska, I.A.; Przanowski, P.; Jackl, J.; Wojtas, B.; Kaminska, B. BIX01294, an Inhibitor of Histone Methyltransferase, Induces Autophagy-Dependent Differentiation of Glioma Stem-like Cells. *Sci. Rep.* **2016**, *6*, 1–15. [[CrossRef](#)]
165. Kato, S.; Weng, Q.Y.; Insko, M.L.; Chen, K.Y.; Muralidhar, S.; Pozniak, J.; Diaz, J.M.S.; Drier, Y.; Nguyen, N.; Lo, J.A.; et al. Gain-of-Function Genetic Alterations of G9a Drive Oncogenesis. *Cancer Discov.* **2020**, *10*, 980–997. [[CrossRef](#)]
166. Liu, S.; Ye, D.; Guo, W.; Yu, W.; He, Y.; Hu, J.; Wang, Y.; Zhang, L.; Liao, Y.; Song, H.; et al. G9a Is Essential for EMT-Mediated Metastasis and Maintenance of Cancer Stem Cell-like Characters in Head and Neck Squamous Cell Carcinoma. *Oncotarget* **2015**, *6*, 6887–6901. [[CrossRef](#)] [[PubMed](#)]
167. Rowbotham, S.P.; Li, F.; Dost, A.F.M.; Louie, S.M.; Marsh, B.P.; Pessina, P.; Anbarasu, C.R.; Brainson, C.F.; Tuminello, S.J.; Lieberman, A.; et al. H3K9 Methyltransferases and Demethylases Control Lung Tumor-Propagating Cells and Lung Cancer Progression. *Nat. Commun.* **2018**, *9*, 1–13. [[CrossRef](#)] [[PubMed](#)]
168. Ciechomska, I.A.; Marciniak, M.P.; Jackl, J.; Kaminska, B. Pre-Treatment or Post-Treatment of Human Glioma Cells with BIX01294, the Inhibitor of Histone Methyltransferase G9a, Sensitizes Cells to Temozolomide. *Front. Pharmacol.* **2018**, *9*, 1271. [[CrossRef](#)]